[
  {
    "clause_index": 1,
    "start_char": 241,
    "end_char": 1856,
    "original": "Execution Copy COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this \u201c Agreement \u201d) is entered into as of June 8, 2018 (the \u201c Execution Date \u201d), by and between Revolution Medicines, Inc. , a corporation organized and existing under the laws of Delaware, having its principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\u201c RevMed \u201d), and Aventis, Inc., a corporation organized and existing under the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\u201c Sanofi \u201d). Sanofi and RevMed are referred to in this Agreement individually as a \u201c Party \u201d and collectively as the \u201c Parties .\u201d RECITALS WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing  protein tyrosine phosphatase 2\u037e WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies\u037e WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications\u037e and WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and Products (as defined below), as further described herein.",
    "ollama_generated": "Execution Copy COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT\n\nThis COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this \"Agreement\") is entered into as of June 8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed\"), and Aventis, Inc., a corporation organized and existing under the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi\"). Sanofi and RevMed are referred to in this Agreement individually as a \"Party\" and collectively as the \"Parties\".\n\nRECITALS\nWHEREAS, Sanofi has demonstrated expertise in pharmaceutical development and commercialization;\nWHEREAS, RevMed possesses unique cancer biology knowledge and related drug discovery capabilities that allow it to develop and optimize drug candidates targeting Src homology region 2-containing protein tyrosine phosphatase 2 (\"SHP2\");\nWHEREAS, Sanofi seeks to expand its portfolio of novel therapies;\nWHEREAS, RevMed is willing to collaborate with Sanofi for the research, development and potential commercialization of such drug candidates and biologic compounds that inhibit SHP2 activity for the treatment of cancer, and potentially other indications;\nWHEREAS, in consideration for the collaboration, RevMed desires to receive from Sanofi certain benefits, as further described herein.\n\nIn this Agreement, the Parties intend to establish a collaboration, whereby Sanofi will acquire licenses with regard to SHP2 Inhibitors and Products (as defined below) from RevMed, and RevMed will grant such licenses to Sanofi, subject to the terms and conditions set forth herein.",
    "contradiction_score": 0.07716462016105652,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 10,
    "start_char": 5302,
    "end_char": 5590,
    "original": "1.6 \u201cAncillary Agreement\u201d means the Co-Promotion  Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
    "ollama_generated": "1.6 \"Ancillary Agreements\" encompass the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply Agreement, any Quality Agreement, and any other agreements entered into between the Parties (or their respective Affiliates) prior to or subsequent to this Agreement. This term also includes any additional agreements that may arise from the performance of this Agreement but shall not be limited thereto.",
    "contradiction_score": 0.006435025949031115,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 11,
    "start_char": 5590,
    "end_char": 6028,
    "original": "1.7 \u201cAntitrust Law \u201d means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the \u201cHSR Act \u201d), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade.",
    "ollama_generated": "1.7 \"Anticompetitive Regulation\" encompasses the Hart-Scott-Rodino Antitrust Improvements Act of 1976, its attendant rules and regulations (hereafter referred to as the \"HSR Act\"), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other applicable laws governing merger control or aimed at preventing, limiting, or regulating actions that might lead to monopolization or market restriction. This definition, however, does not extend to regulatory actions that promote competition or encourage fair trade practices.",
    "contradiction_score": 0.07247576117515564,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 16,
    "start_char": 7761,
    "end_char": 10617,
    "original": "1.12 \u201cChange of Control \u201d means with respect to a Party (a) any sale, exchange, transfer, or issuance to or acquisition in one transaction or a series of related transactions by one or more Third Parties of units and/or shares of equity (as applicable) representing 50% or more of the aggregate ordinary voting power entitled to vote for the election of directors or managers represented by the issued and outstanding units of equity of such Party (or any Affiliate that directly or indirectly controls such Party (such Affiliate, the \u201c Parent \u201d)), whether such sale, exchange, transfer, issuance or acquisition is made directly or indirectly, by merger or otherwise, or beneficially or of record (collectively, a \u201c Stock Sale \u201d)\u037e (b) a merger or consolidation under Applicable Law of such Party or a Parent with a Third Party, other than a merger or consolidation in which the units and/or shares of equity of such Party or Parent outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or are exchanged for units and/or shares of equity which represent, immediately following such merger or consolidation, 50% or more of the aggregate ordinary voting power of such units and/or shares of equity of the surviving or resulting entity or a parent entity of such surviving or resulting entity, whether direct or indirect (collectively, a \u201cMerger \u201d)\u037e (c) a sale, lease, transfer, exclusive license or other disposition of all or substantially all of the assets of such Party or a Parent to one or more Third Parties in one transaction or a series of related transactions (collectively, the \u201c Asset Transfer \u201d). Notwithstanding the foregoing, a purchase of shares in a Stock Sale by one or more Third Parties in a bona fide financing transaction the primary purpose of which is to raise working capital for RevMed or to acquire assets from a Third Party (in either case including one or more public offerings) shall not constitute a Change of Control even if such Third Parties collectively negotiate or receive their rights as security holders in such financing transaction(s), except that such exemption shall not apply with respect to any Change of Control that would result in any Major Biopharmaceutical Company having more than 50% of the aggregate ordinary voting power in RevMed or its Parent. The Parent of a Party for purposes of this Section 1.12 shall not include any Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 Excluded Investor, provided that the applicable Stock Sale, Merger or Asset Transfer does not result in any Major Biopharmaceutical Company having more than 50% of the aggregate ordinary voting power in, or control over all or substantially all of the assets of, RevMed or its Parent or any surviving or resulting entity or a parent entity of such surviving or resulting entity.",
    "ollama_generated": "1.12 \"Control Shift\" denotes, in reference to a Party:\n\n(a) Any direct or indirect acquisition by one or more Third Parties, through a single transaction or a series of related transactions, of units and/or shares representing over 50% of the aggregate voting power at a general meeting for the election of directors or managers, held by the issued and outstanding units of equity of such Party (or any Affiliate that directly or indirectly controls said Party, herein referred to as the \"Controlling Entity\"), irrespective of the method of acquisition \u2014 be it via purchase, exchange, transfer, issuance, merger, or other means.\n\n(b) A merger or consolidation under Applicable Law involving such Party or the Controlling Entity with a Third Party, except in cases where the units and/or shares of equity held by the Party or the Controlling Entity prior to the merger or consolidation continue to represent, or are converted into or exchanged for units and/or shares that represent, 50% or more of the aggregate voting power of the surviving or resulting entity or a parent entity of such surviving or resulting entity.\n\n(c) The sale, lease, transfer, exclusive licensing, or other disposal of all or substantially all assets of such Party or the Controlling Entity to one or more Third Parties, as part of a single transaction or series of related transactions.\n\nNotwithstanding the above, a financing transaction aimed at raising working capital for the relevant entity (RevMed) or acquiring assets from a Third Party will not be considered a \"Control Shift,\" even if the Third Parties involved negotiate or receive their rights as security holders in such transactions; provided that no Change of Control results in any Major Biopharmaceutical Company holding over 50% of the aggregate voting power within RevMed, its Controlling Entity, or any subsequent surviving or resulting entity. The Controlling Entity of a Party, for the purposes of this Section 1.12, excludes any Excluded Investor; however, the applicable Shift in Control, merger, or asset transfer will not be exempt if it leads to any Major Biopharmaceutical Company holding over 50% of the aggregate voting power within RevMed, its Controlling Entity, or any surviving or resulting entity or a parent entity of such surviving or resulting entity.",
    "contradiction_score": 0.25058713555336,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 17,
    "start_char": 10617,
    "end_char": 10943,
    "original": "1.13 \u201cClinical Trial\u201d means any clinical investigation conducted on human subjects, as that term is defined in FDA regulations at 21 C.F.R. \u00a7 312.3. Without limiting the foregoing, Clinical Trial includes any Phase 1 Clinical Trial, Phase 2 Clinical Trial, Phase 3 Clinical Trial, Phase 4 Study or variations of the foregoing.",
    "ollama_generated": "1.13 \"Qualified Research Study\" refers to any investigation involving human subjects that meets the definition set forth in FDA regulations at 21 C.F.R. \u00a7 312.3. This term encompasses, but is not limited to, pre-market (Phase 1, Phase 2, and Phase 3) clinical trials, post-market (Phase 4) studies, as well as any adaptations or modifications of these types of research.\n\nNote: The intention behind this revised clause is to broaden the scope of the original term \"Clinical Trial\" while maintaining professionalism and clarity. The new term \"Qualified Research Study\" includes not only traditional clinical trials but also post-market studies and variations thereof, effectively expanding the scope beyond what was initially defined.",
    "contradiction_score": 0.006996903568506241,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 21,
    "start_char": 12063,
    "end_char": 12337,
    "original": "1.17 \u201cCommercially Reasonable Efforts\u201d means: (a) with respect to Sanofi, [***], consistent with [***] that [***], taking into account [***], including [***] and (b) with respect to RevMed, [***], consistent with [***] that [***], taking into account [***], including [***].",
    "ollama_generated": "1.17 \"Diligent but not Exclusive Efforts\" means: (a) for Sanofi, a good faith and diligent effort to comply, considering industry standards and practices that apply generally in the pharmaceutical industry, while being mindful of other obligations, encompassing flexibility to adapt to unforeseen circumstances, and (b) for RevMed, a reasonable and conscientious effort to comply, respecting the guidelines set within the medical device sector, acknowledging any competing priorities, covering a range of strategies to tackle potential complications.",
    "contradiction_score": 0.2078072428703308,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 26,
    "start_char": 14619,
    "end_char": 15342,
    "original": "1.22 \u201cControl\u201d or \u201cControlled\u201d means, with respect to any item of Know-How,  Patent Right, other intellectual property right or Regulatory Material, a Party has the ability (whether by sole, joint or other ownership interest, license, sublicense or otherwise, and including any such abilities which are contingent) (other than by operation of the licenses granted in this Agreement) to grant a license, sublicense, access or right to use (as applicable) under such item of Know-How,  Patent Right, other intellectual property right or Regulatory Material to the other Party on the terms and conditions set forth herein at the time of such grant, in each case without breaching the terms of any agreement with a Third Party.",
    "ollama_generated": "1.22 \"Control\" or \"Controlled\" refers, in relation to any item of Know-How, Patent Right, other intellectual property right, or Regulatory Material, that a Party holds a position (whether through direct or indirect ownership, licensing, sub-licensing, or any other means, including those with conditions) that allows them, at their discretion and not in violation of any existing agreements with Third Parties, to restrict the other Party's access to, or use of, such item on the terms and conditions outlined in this Agreement. This does not include any control granted under the licenses provided within this Agreement.",
    "contradiction_score": 0.08440446853637695,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 29,
    "start_char": 15539,
    "end_char": 15652,
    "original": "1.25 \u201cDesignated Senior Officer\u201d means: (a) with respect to RevMed, [***] and, (b) with respect to Sanofi, [***].",
    "ollama_generated": "1.25 \"Designated Senior Officer\" denotes: (a) in reference to RevMed and [***], the individual assigned with such responsibility, and (b) in reference to Sanofi, the person appointed who may delegate their duties to a subordinate, as approved by Sanofi's management.\n\nIn this revised clause, the responsibilities of the \"Designated Senior Officer\" are slightly broadened for Sanofi, allowing them to delegate their duties to a subordinate, while maintaining the original meaning in reference to RevMed and [***].",
    "contradiction_score": 0.018794717267155647,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 38,
    "start_char": 19704,
    "end_char": 19800,
    "original": "1.34 \u201cFDA\u201d means the United States Food and Drug Administration or any successor entity thereto.",
    "ollama_generated": "1.34 \"FDA\" denotes the United States Food and Drug Administration or any entity that may subsequently assume its regulatory responsibilities.\n\nChanges made: The original clause refers to the FDA as a current entity, while the rewritten clause allows for the possibility of another entity taking over the FDA's role in the future.",
    "contradiction_score": 0.010110649280250072,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 43,
    "start_char": 21178,
    "end_char": 21398,
    "original": "1.39 \u201cFTE Costs\u201d means, with respect to a Party for any period, the applicable FTE Rate multiplied by the applicable number of FTEs of such Party performing the applicable activity described hereunder during such period.",
    "modified": "1.39 \"Applicable FTE Expenditure\" denotes, in reference to each Party within a given timeframe, the inverse of the relevant FTE Rate multiplied by the number of Full-Time Equivalents from said Party actively engaged in the specified activity as detailed herein during that particular duration.\n\nIn this revised clause, the focus has shifted from calculating costs to understanding expenditure, and the multiplication operation is inverted. This change does not significantly alter the meaning but presents a subtle difference in the perspective from which the calculation is viewed.",
    "contradiction_score": 0.6871678233146667,
    "kept": true
  },
  {
    "clause_index": 54,
    "start_char": 24542,
    "end_char": 24968,
    "original": "1.50 \u201cIND\u201d means (a) in the United States, an Investigational New Drug Application, as defined in the Act, that is required to be filed with the FDA before conducting a Clinical Trial ( including all supplements and amendments that may be filed with respect to the foregoing)\u037e and (b) any foreign counterpart of the foregoing filed with a Regulatory Authority in conformance with the requirements of such Regulatory Authority.",
    "modified": "1.50 \"IND\" denotes (a) within the United States, an Investigational New Drug Application, as per the Act, that is not necessarily required to be submitted to the FDA prior to initiating a Clinical Trial (although it may be filed for regulatory purposes), including all subsequent supplements and amendments relating thereto; and (b) any equivalent overseas submission made to a Regulatory Authority, in compliance with the regulations of such governing body.\n\nIn this revised clause, the obligation to file an IND before conducting a Clinical Trial has been weakened by changing \"required\" to \"not necessarily required.\" Additionally, the condition that an IND must be filed prior to initiating a Clinical Trial has been inverted, suggesting that while an IND may be filed, it is not always necessary. Lastly, the responsibility for filing an IND when conducting a Clinical Trial has been shifted slightly by adding \"although it may be filed\" and rephrasing \"that is required to be filed\" as \"that is not necessarily required to be submitted.\"",
    "contradiction_score": 0.842088520526886,
    "kept": true
  },
  {
    "clause_index": 55,
    "start_char": 24968,
    "end_char": 25126,
    "original": "1.51 \u201cIndication\u201d means a type of cancer for which Regulatory Approval for a Product is being sought that (i) is distinct from other types of cancer by [***].",
    "ollama_generated": "1.51 \"Designated Cancer\" refers to a specific form of malignancy where the pursuit of Regulatory Approval for a Product is underway, and such cancer demonstrates unique characteristics that (i) differ significantly from other known types of cancer in terms of its clinical manifestations, genetic mutations, or response to treatment.\n\nIn this revised clause, I have attempted to maintain the original meaning while emphasizing the uniqueness and distinctiveness of the designated cancer, which could potentially be interpreted as a weakening of the obligation, as it sets a higher standard for differentiation from other types of cancer.",
    "contradiction_score": 0.04281479865312576,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 56,
    "start_char": 25130,
    "end_char": 25188,
    "original": "1.52 \u201cInitial R&D Term\u201d means the first [***] of the Term.",
    "modified": "1.52 \"Initial R&D Term\" shall refer to the latter part of the Term initially agreed upon.",
    "contradiction_score": 0.9988160133361816,
    "kept": true
  },
  {
    "clause_index": 59,
    "start_char": 25401,
    "end_char": 25489,
    "original": "1.55 \u201cJoint Program Technology\u201d means Joint Program Know-How  and Joint Program Patents.",
    "ollama_generated": "1.55 \"Technology Related to the Joint Program\" shall encompass both the Knowledge Attributable to the Joint Program (hereinafter referred as \"Joint Program Know-How\") and the Patentable Inventions Arising from the Joint Program (hereinafter referred as \"Joint Program Patents\"). However, each party shall bear sole responsibility for any third-party claims or liabilities arising from their respective contributions to this Technology.\n\nThis revised clause defines a broader term (\"Technology Related to the Joint Program\") that includes both Joint Program Know-How and Joint Program Patents, but it also clarifies that each party assumes individual responsibility for any third-party claims or liabilities related to their specific contributions to this technology. This could potentially shift some of the liability and risk from one party to another, depending on the nature and quality of their respective contributions.",
    "contradiction_score": 0.0017556380480527878,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 62,
    "start_char": 26466,
    "end_char": 26592,
    "original": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 1.58 \u201cLicensed Territory\u201d means all countries and territories of the world.",
    "modified": "Clause:\nREVISION: In the initial offering of REVOLUTION MEDICINES, INC., dated 1/17/2020 (the \"Offering\"), Section 1.58: \"Excluded Territory\" designates the countries and territories of the world where the Company does not hold licensing rights or obligations.",
    "contradiction_score": 0.9388839602470398,
    "kept": true
  },
  {
    "clause_index": 63,
    "start_char": 26597,
    "end_char": 26661,
    "original": "1.59 \u201cLine of Therapy\u201d means the treatment with a Product [***].",
    "ollama_generated": "1.59 \"Line of Therapeutic Approach\" denotes the application of a given Product for therapeutic purposes. [***] is the product in question.",
    "contradiction_score": 0.012236545793712139,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 68,
    "start_char": 27583,
    "end_char": 28199,
    "original": "1.64 \u201cManufacture\u201d and \u201cManufacturing\u201d mean activities directed to manufacturing, processing, filling, finishing, packaging, labeling, quality assurance testing and release, storing and transporting any Product, SHP2 Inhibitors or any intermediate or component thereof, including manufacturing and analytical development, process and formulation development, process qualification, process validation, scale-up,  pre-clinical,  clinical and commercial manufacture and analytic development, product characterization, stability testing, quality assurance and quality control, and chemistry, manufacturing and controls.",
    "ollama_generated": "1.64 The terms \"Manufacture\" and \"Manufacturing\" encompass all actions pertaining to the production, preparation, assembly, packaging, labeling, quality control testing and authorization, storage, and shipping of any Product, SHP2 Inhibitors, or related intermediates or components. This includes research and development activities such as analytical and process development, process qualification, validation, scale-up, pre-clinical, clinical, and commercial production; product characterization, stability testing, quality control and assurance, and chemical processes, collectively referred to as chemistry, manufacturing, and controls. However, it is important to note that while we shall perform these tasks diligently, the ultimate responsibility for compliance with regulatory standards rests solely with you.",
    "contradiction_score": 0.001981273526325822,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 80,
    "start_char": 32031,
    "end_char": 32498,
    "original": "In the event that a Product is sold in any country in the form of a Combination Product, Net Sales of such Combination Product shall be adjusted by [***]\u037e provided that the invoice price [***]. If either such Product that contains the SHP2 Inhibitor(s) as its sole active ingredient or any such product that contains active ingredient(s) other than the SHP2 Inhibitor(s) is not sold separately in a particular country, then the adjustment to Net Sales shall be [***].",
    "modified": "In cases where a Product is marketed as a Combination Product in any nation, the net revenue of such Combination Product will be subject to an adjustment. However, this adjustment will only apply if the invoice price adheres to the specified criteria. If neither the product containing SHP2 Inhibitor(s) as its exclusive active ingredient nor a product with active ingredients other than SHP2 Inhibitor(s) is independently sold in a particular country, then the adjustment to net revenue remains at the discretion of the selling party.",
    "contradiction_score": 0.6341649889945984,
    "kept": true
  },
  {
    "clause_index": 94,
    "start_char": 38017,
    "end_char": 38158,
    "original": "1.82 \u201cProduct\u201d means any pharmaceutical preparation in final form containing a SHP2 Inhibitor, alone or in the form of a Combination Product.",
    "modified": "1.82 \"Covered Product\" refers to any ultimate pharmaceutical composition that comprises a SHP2 Inhibitor, either singularly or as part of a Multicomponent Formulation.\n\nIn this revised clause, the term \"Product\" has been changed to \"Covered Product\", and \"any pharmaceutical preparation in final form\" has been replaced with \"any ultimate pharmaceutical composition\". Furthermore, \"SHP2 Inhibitor\" remains the same, but \"Combination Product\" has been renamed to \"Multicomponent Formulation\". This change introduces a broader term that might encompass not only combination products but also any multi-component formulations.",
    "contradiction_score": 0.5567765235900879,
    "kept": true
  },
  {
    "clause_index": 96,
    "start_char": 38638,
    "end_char": 38839,
    "original": "1.84 \u201cPublication\u201d means any release of information, including any presentation, which information (a) has not been disclosed pursuant to Section 11.3 or (b) has not previously been publicly disclosed.",
    "modified": "1.84 \"Dissemination\" denotes the distribution or sharing of any data or material that: (a) is not subject to the confidentiality provisions outlined in Section 11.3, and (b) has yet to be made accessible to the general public.\n\n(Note: This revised clause weakens the obligation by replacing \"Publication\" with \"Dissemination\", which implies a broader scope of information transfer, including but not limited to formal presentations.)",
    "contradiction_score": 0.906417965888977,
    "kept": true
  },
  {
    "clause_index": 100,
    "start_char": 40224,
    "end_char": 40898,
    "original": "1.88 \u201cRegulatory Exclusivity\u201d means any rights or protections which are recognized, afforded or granted by the FDA or any other Regulatory Authority in any country or region of the Territory pursuant to Applicable Laws of such country or region, in association with the marketing authorization of the Product, providing the Product[***] a period of marketing exclusivity, during which a Regulatory Authority recognizing, affording or granting such marketing exclusivity will refrain from either reviewing or approving a marketing authorization application or similar regulatory submission, submitted by a Third Party seeking to market a Generic Product of such Product[***].",
    "ollama_generated": "1.88 \"Marketing Exclusivity Rights\" refers to any exclusive rights or protections conferred by the FDA or any other Regulatory Authority in any given country or region within the Territory, in accordance with applicable laws of such jurisdiction, relating to the marketing authorization of the Product. This exclusive status grants the Product a period of protection from regulatory review or approval, during which time, a Regulatory Authority acknowledging these rights will not process applications for marketing authorizations submitted by Third Parties seeking to market a Generic Product that is equivalent to the protected Product.",
    "contradiction_score": 0.038359809666872025,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 103,
    "start_char": 41799,
    "end_char": 41991,
    "original": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 1.91 \u201cResearch\u201d means all research activities conducted by or on behalf of either Party or the Parties jointly pursuant to the Research Plan.",
    "modified": "Clause:\n\nSource: REVOLUTION MEDICINES, INC., S-1, 1/17/2020\n1.91 \"Research\" denotes all research activities initiated or undertaken unilaterally by either Party, without any obligation for the other to participate, as outlined in the Research Plan.",
    "contradiction_score": 0.526242733001709,
    "kept": true
  },
  {
    "clause_index": 107,
    "start_char": 42748,
    "end_char": 43073,
    "original": "1.95 \u201cRevMed Background Patents\u201d means, subject to Section 3.1(b), any Patent Right (a) (i) that is Controlled by RevMed or its Affiliates as of the Effective Date\u037e or (ii) that comes into the Control of RevMed or its Affiliates during the Term, excluding the RevMed Sole Program Patents and Joint Program Patents\u037e and [***].",
    "ollama_generated": "1.95 \"RevMed Background Patents\" refers, with exceptions outlined in Section 3.1(b), to any Patent Right (a) that is currently under RevMed or its Affiliates' control on the Effective Date, or (b) gains such control by RevMed or its Affiliates during the Term, excluding the RevMed Sole Program Patents and Joint Program Patents; however, it does not include any Patent Right that was initially controlled by the Counterparty or any entity affiliated with the Counterparty prior to the Effective Date.\n\nIn this revised clause, the focus shifts responsibility for certain patents from RevMed to the Counterparty, should those patents have been under their control before the Effective Date. This change is reflected in the added phrase \"[it does not include any Patent Right that was initially controlled by the Counterparty or any entity affiliated with the Counterparty prior to the Effective Date].\"",
    "contradiction_score": 0.25943467020988464,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 108,
    "start_char": 43077,
    "end_char": 43176,
    "original": "1.96 \u201cRevMed Background Technology\u201d means RevMed Background Patents and RevMed Background Know-How.",
    "modified": "1.96 \"RevMed Foreground Technology\" encompasses all innovations and know-how developed by the parties during the term of this agreement, excluding RevMed Background Patents and Know-How. The responsibility for any pre-existing patents or know-how related to the background shall remain with RevMed.",
    "contradiction_score": 0.9975639581680298,
    "kept": true
  },
  {
    "clause_index": 115,
    "start_char": 44223,
    "end_char": 44393,
    "original": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 1.103  \u201cRevMed Sole Program Know-How\u201d  means all Program Inventions owned solely by RevMed pursuant to Section 10.1(a).",
    "ollama_generated": "Clause:\nRevised: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 1.103  \"Program Inventions Owned Exclusively by RevMed\" refers to all inventions that are owned solely by a third party but have been exclusively licensed to RevMed in accordance with Section 10.1(a).\n\nExplanation: The revised clause introduces a slight change where the ownership of Program Inventions has been shifted from RevMed (Source) to a third party, but RevMed has obtained exclusive licensing rights through Section 10.1(a). This shift in responsibility and ownership allows for flexibility when it comes to the development and exploitation of the inventions.",
    "contradiction_score": 0.0856103003025055,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 116,
    "start_char": 44400,
    "end_char": 44514,
    "original": "1.104  \u201cRevMed Sole Program Patents\u201d means any Patent Right covering or claiming the RevMed Sole Program Know-How.",
    "ollama_generated": "1.104 \"RevMed Sole Program Patents\" refers to any and all Patent Rights that may be asserted in relation to, or claim rights over, the proprietary knowledge represented by the RevMed Sole Program (hereafter referred to as \"RevMed Know-How\"), while recognizing that such patents are not necessarily exclusively owned by RevMed.",
    "contradiction_score": 0.0020349251572042704,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 120,
    "start_char": 44956,
    "end_char": 45249,
    "original": "1.108  \u201cSanofi R&D Out-Of-Pocket  Costs\u201d means amount paid by Sanofi in cash to Third Parties for good and services required in order for Sanofi to conduct Research or Development of Product in the Field in accordance with the Research Plan or Development Plan for such Product, as applicable.",
    "ollama_generated": "1.108 \"Sanofi R&D Out-Of-Pocket Costs\" refers to any cash expenditures made by Sanofi towards third parties for goods and services deemed necessary for the conduct of Research or Development of a Product in the designated Field, as stipulated in the applicable Research or Development Plan. However, it is understood that Sanofi shall not be obligated to cover costs incurred due to the unforeseen or unnecessary expenditure of resources, subject to reasonable discretion.",
    "contradiction_score": 0.007535945624113083,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 122,
    "start_char": 45372,
    "end_char": 45486,
    "original": "1.110  \u201cSanofi Sole Program Patents\u201d means any Patent Right covering or claiming the Sanofi Sole Program Know-How.",
    "ollama_generated": "1.110 \"Program Know-How Covered by Sanofi Exclusive Patents\" denotes any Patent Rights that are exclusively owned by Sanofi and encompass or reference the Know-How related to the Sanofi Exclusive Program.\n\nIn this revised version, the focus shifts from the patents covering the program (Sanofi Sole Program Patents) to the know-how being covered by Sanofi's exclusive patents (Program Know-How Covered by Sanofi Exclusive Patents). This change subtly suggests a broader scope of protection for the program's know-how, as it now includes any patent rights that reference this know-how, not just those specifically covering it.",
    "contradiction_score": 0.022450339049100876,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 146,
    "start_char": 52629,
    "end_char": 52640,
    "original": "Article II.",
    "ollama_generated": "Article II.\n\nIn the event of any discrepancy or difference arising between the Parties regarding the interpretation of this Agreement, it shall be the exclusive responsibility of the Company to initiate the process of resolution within ten (10) business days following written notice by either Party. Any dispute not resolved amicably within said period shall be resolved through binding arbitration in accordance with the rules of the American Arbitration Association.\n\nIn this revised clause, the responsibility for resolving disputes has been shifted from a joint effort to an exclusive responsibility of the Company. This means that if there's a dispute, it is the company who must initiate the resolution process within ten (10) business days following written notice by either Party. If no resolution is reached amicably within this timeframe, arbitration will be necessary. However, it is important to note that the original clause still requires a good-faith effort towards an amicable resolution before resorting to arbitration.",
    "contradiction_score": 0.002878730883821845,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 149,
    "start_char": 54177,
    "end_char": 54368,
    "original": "(a) Composition . The JSC shall consist of three senior executives of each Party, with at least one such senior executive from each such Party holding the position of vice president or above.",
    "modified": "(b) Composition . Each Party shall appoint three of their most senior executives, with at least one appointee from each Party being in a position equal to or above that of a vice president. The collective group constitutes the JSC.",
    "contradiction_score": 0.7731261849403381,
    "kept": true
  },
  {
    "clause_index": 150,
    "start_char": 54370,
    "end_char": 54468,
    "original": "(b) Function and Powers . The JSC shall manage the overall Collaboration, and shall in particular:",
    "ollama_generated": "(b) Function and Authority. The Joint Steering Committee (JSC) shall be delegated overall control of the Collaboration, and is hereby empowered to:\n\nIn this role, it is important to note that while the JSC shall strive for effective management, the parties acknowledge that the success of the Collaboration may depend on factors outside of the JSC's direct control. Additionally, the JSC's authority is not absolute and shall be exercised in accordance with the terms and conditions set forth in this Agreement. The parties retain their respective autonomy and decision-making rights, subject to any decisions made by the JSC under its delegated powers.",
    "contradiction_score": 0.005081252660602331,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 167,
    "start_char": 62245,
    "end_char": 62501,
    "original": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 (a) Composition . The JMC shall consist of three representatives of each Party that have knowledge and expertise in the manufacture or supply management of pharmaceutical or biologic products in the Field.",
    "modified": "Clause:\nAlteration: Shift responsibility from both parties to a single representative from Revolution Medicines, Inc.\n\nRevolution Medicines, INC., S-1, 1/17/2020 (a) Composition . The JMC shall consist of one representative from Revolution Medicines, Inc. who possesses knowledge and expertise in the manufacture or supply management of pharmaceutical or biologic products within the Field, with input from the counterparty for consultation purposes.",
    "contradiction_score": 0.9042971134185791,
    "kept": true
  },
  {
    "clause_index": 168,
    "start_char": 62501,
    "end_char": 62758,
    "original": "(b) No Power or Authority\u037e Function . The JMC shall not have any power or authority (including decision making) with respect to Collaboration matters. Rather, the JMC shall serve as an information-sharing forum for the Parties with respect to the following:",
    "ollama_generated": "(b) Delegated Power and Consultative Role: The Joint Management Committee (JMC) is vested with a consultative role and has no decision-making authority regarding Collaboration matters. It shall act as a platform for information exchange among the Parties, focusing on the following areas:\n\nThis rewritten clause shifts the JMC's role from a non-powerful information-sharing forum to a consultative body without decision-making authority. The focus remains on being an information-sharing forum, but the phraseology suggests that the JMC may have some influence or input into the decisions made by the Parties.",
    "contradiction_score": 0.36640697717666626,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 170,
    "start_char": 63455,
    "end_char": 63914,
    "original": "2.7 Limitation of Committee Authority . Each Committee shall only have the powers expressly assigned to it in this Article II and elsewhere in this Agreement and shall not have the authority to: (a) modify or amend the terms and conditions of this Agreement\u037e (b) waive either Party\u2019s compliance with the terms and conditions of this Agreement\u037e or (c) determine any issue in a manner that would conflict with the express terms and conditions of this Agreement.",
    "modified": "2.7 Expanded Committee Powers and Responsibilities. Each Committee shall possess all powers necessary to carry out their duties as explicitly stated in this Article II and elsewhere in this Agreement, including but not limited to: (a) proposing modifications or amendments to the terms and conditions of this Agreement; (b) recommending waivers of either Party's compliance with the terms and conditions of this Agreement; and (c) making decisions on any issue that does not explicitly conflict with the express terms and conditions of this Agreement, subject to final approval by the parties. In all cases, the Committees shall act within the spirit and intent of this Agreement.",
    "contradiction_score": 0.9875530004501343,
    "kept": true
  },
  {
    "clause_index": 173,
    "start_char": 65526,
    "end_char": 65591,
    "original": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 (b) Meetings .",
    "ollama_generated": "Clause:\nRevised: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 (b) Meetings .\n\nRewritten: Meetings (optional but strongly encouraged)\n\nExplanation: In this revised clause, the original \"Meetings\" is maintained, but the obligation has been weakened to an optional requirement, rather than a mandatory one. The phrase \"strongly encouraged\" indicates that while not compulsory, it is recommended for compliance. This change may reflect a more flexible approach and potentially accommodate more varied circumstances without strictly binding parties to regular meetings.",
    "contradiction_score": 0.18769539892673492,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 182,
    "start_char": 70001,
    "end_char": 70211,
    "original": "(i) [***] (ii) [***] (iii) [***] or (iv) [***]. Notwithstanding anything to the contrary in this Agreement, except as expressly set forth in Section 4.2(a)(i)(A) and, if applicable, Section 4.2(a)(i)(B), [***]:",
    "ollama_generated": "(i) [***] (ii) [***] (iii) [***] or (iv) [***]. Despite any provisions to the contrary in this Agreement, and except as explicitly provided for in Section 4.2(a)(i)(A) and, if relevant, Section 4.2(a)(i)(B), [***], it is understood that [***] will bear no additional obligations or responsibilities beyond those expressly stated herein.\n\nIn this revised clause, the original statement of \"Notwithstanding anything to the contrary in this Agreement\" has been changed to \"Despite any provisions to the contrary in this Agreement,\" which subtly shifts the responsibility from the party performing the action ([***]) to the other parties involved in the agreement, implying that any additional obligations or responsibilities beyond those expressly stated are not applicable unless specifically mentioned.",
    "contradiction_score": 0.019781451672315598,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 184,
    "start_char": 70999,
    "end_char": 72656,
    "original": "2.11 Discontinuation of Committee s. The activities to be performed by each Committee shall solely relate to governance under this Agreement, and are not intended to be or involve the delivery of services. Each Committee shall continue to exist until the Parties mutually agree to disband such Committee, or if RevMed provides Sanofi with written notification of its decision to discontinue its participation in such Committee\u037e provided that (a) the JPC shall disband upon [***], (b) the JCC shall disband if [***]\u037e (c) the JRDC shall disband upon [***]\u037e and (d) the JMC shall disband upon [***]. If a Committee is so disbanded, such Committee shall have no further obligations under this Agreement and, thereafter, the Alliance Managers shall be the contact persons for the exchange of information under this Agreement and decisions of such Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 Committee shall be decisions of Sanofi. Upon disbandment of the JRDC, JCC, JPC or JMC or at any time in the JSC\u2019s discretion, the JSC may assume from the JRDC, JCC, JPC or JMC any and all of such Committees\u2019 respective responsibilities. Notwithstanding anything to the contrary in Section 2.8(b)(i), following substantial completion of RevMed\u2019s activities under the Research Plan and Development Plan, the JRDC shall meet no less frequently than [***], provided that there are bona fide agenda items for such meetings. If RevMed undergoes a Change of Control following substantial completion of RevMed\u2019s activities under the Research Plan and Development Plan, [***] may, in its sole discretion, [***]. The JSC shall disband if all other Committees have disbanded.",
    "ollama_generated": "2.11 Termination of Committees: The roles assigned to each Committee under this Agreement are primarily governance-focused and do not encompass service delivery. Each Committee shall persist until the Parties reach a mutual consensus to dissolve it, or if Sanofi receives written notice from RevMed indicating its intention to withdraw from such Committee. However, exceptions apply to specific Committees as follows: (a) The JPC will disband on [***], (b) the JCC will cease operations if [***], (c) the JRDC will dissolve upon [***], and (d) the JMC will terminate upon [***]. Upon the dissolution of any Committee, it shall no longer bear any obligations under this Agreement, with the Alliance Managers serving as the primary points of contact for information exchange and decision-making. In the event of the disbandment of the JRDC, JCC, JPC, or JMC, or at any time at the discretion of the JSC, the JSC may assume all responsibilities previously held by these Committees. Contrary to Section 2.8(b)(i), following substantial completion of RevMed's tasks under the Research and Development Plans, the JRDC will convene no less than [***], provided there are legitimate agenda items for such meetings. In case of a Change of Control at RevMed following the substantial completion of its activities under the Research Plan and Development Plan, [***] retains the right, in its sole discretion, to [***]. The JSC will disband only after all other Committees have been dissolved.\n\nThis revised clause weakens the obligation for RevMed to continue participating in committees by allowing it to withdraw with written notice, and shifts some responsibilities from the committees to the JSC upon their dissolution. The frequency of JRDC meetings is also adjusted to provide flexibility based on agenda items rather than a strict schedule.",
    "contradiction_score": 0.3998454213142395,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 185,
    "start_char": 72668,
    "end_char": 72680,
    "original": "Article III.",
    "ollama_generated": "Article III - Modification of Obligations\n\nUpon the occurrence of any event that may materially affect one party's ability to fulfill its obligations under this Agreement, the affected party shall promptly notify the other party in writing and endeavor, in good faith, to find a mutually acceptable resolution. However, the affected party shall not be deemed to have breached this Agreement by reason of its failure to perform any of its obligations if it is unable to do so due to such event. The burden of proving such inability shall rest with the non-performing party.\n\nIn contrast, the original clause stated:\n\nArticle III - Performance Obligations\n\nEach party acknowledges and agrees that it will fulfill all its obligations under this Agreement without any excuses or exceptions. Failure to perform any of such obligations shall constitute a breach of this Agreement. The non-performing party shall be solely liable for any damages caused by such breach.",
    "contradiction_score": 0.09573830664157867,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 191,
    "start_char": 74085,
    "end_char": 74742,
    "original": "3.2 License to RevMed . Subject to the terms and conditions of this Agreement, Sanofi hereby grants to RevMed a non-exclusive,  royalty-free sublicense (which shall only be further sub-licensable  (a) to RevMed\u2019s Subsidiaries, (b) to the Permitted Contractors or Researchers, and (c) solely with Sanofi\u2019s prior written consent, such consent not to be unreasonably withheld, delayed or conditioned, to Third Parties who are not Permitted Contractors or Researchers) under the rights exclusively licensed to Sanofi pursuant to Section 3.1, solely to the extent necessary for RevMed to perform its obligations under this Agreement and the Ancillary Agreements.",
    "ollama_generated": "3.2 Sublicense Granted by Sanofi. Granting the terms and conditions of this Agreement, RevMed is hereby given a non-exclusive, royalty-free, and unlimited (within the scope specified below) sublicense. This license can be further sub-licensed:\n\n(a) to RevMed's Subsidiaries,\n(b) to Permitted Contractors or Researchers for their exclusive use, and\n(c) with Sanofi's prior written consent (which will not unreasonably be withheld, delayed, or subjected to conditions), to Third Parties who are neither Permitted Contractors nor Researchers. However, this sublicense is only extended to the minimum extent required for RevMed to fulfill its obligations under this Agreement and the Ancillary Agreements, rather than being granted broadly as in Section 3.1.",
    "contradiction_score": 0.025528769940137863,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 193,
    "start_char": 75044,
    "end_char": 75124,
    "original": "Notwithstanding anything to the contrary in this Agreement, nothing shall [***].",
    "ollama_generated": "Notwithstanding any provisions in this Agreement to the contrary, the Company reserves the right to unilaterally amend or terminate this Agreement without prior notice or liability.\n\nExplanation: The original clause was a general statement that nothing specified in the agreement would prevent something from happening. I've rewritten it to give the company the power to alter or end the agreement on their own terms, without notification or responsibility for any consequences. This significantly weakens the obligation on the company and shifts the burden of potential negative impacts onto the other party.",
    "contradiction_score": 0.1289571076631546,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 199,
    "start_char": 79043,
    "end_char": 79459,
    "original": "(a) Except pursuant to or as expressly permitted by this Agreement, RevMed shall not, shall cause its Affiliates not to, conduct or agree to conduct, outside of the Collaboration, on its own or together with one or more Third Parties, the Research, Development or Commercialization of any product that contains a SHP2 Inhibitor, including any SHP1-SHP2 Dual Inhibitor that [***]. For purposes of this Section, [***].",
    "ollama_generated": "(a) Except in accordance with, or as explicitly authorized by, this Agreement, RevMed is granted the discretion not to, and shall not obligate its Affiliates to abstain from, independently or jointly with one or more Third Parties, engaging in, or agreeing to engage in, outside the Collaboration, the Research, Development, or Commercialization of any product that incorporates a SHP2 Inhibitor, including any SHP1-SHP2 Dual Inhibitor. For the purposes of this Section, RevMed shall have the discretion to determine which products fall under this definition.",
    "contradiction_score": 0.009876860305666924,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 233,
    "start_char": 107027,
    "end_char": 107896,
    "original": "(c) Pre-Registrational  Meeting . After obtaining early Development data and results under the Development Plan for a particular Product, in the event the JRDC determines to further Develop such Product for Marketing Approval, the JRDC shall develop a package setting forth such data and results, a planned regulatory strategy for the Development of such Product for a defined indication in the Field, the protocol synopses for each Registrational Clinical Trial included in the applicable Registration Program, any other Development activities to be conducted in support of such regulatory strategy, any other materials as may be required by the FDA, EMA, or PMDA or other Regulatory Authority for the Pre-Registrational Meetings for the applicable Products, and the Party responsible for conducting each Development activity under such package (the \u201c Data Package \u201d).",
    "ollama_generated": "(c) Pre-Registration Meeting Obligation. Upon obtaining early Development data and results as outlined in the Development Plan for a given Product, if the JRDC elects to pursue Marketing Approval for such Product, it shall compile a comprehensive document detailing these data and results, a proposed regulatory strategy for the Product's development for a specific indication within the Field, synopses of each Clinical Trial protocol included in the applicable Registration Program, any additional Development activities necessary to support this regulatory strategy, any materials demanded by the FDA, EMA, PMDA, or other Regulatory Authority for Pre-Registration Meetings regarding the said Products, and the Party assigned to undertake each Development task under this document (hereafter referred to as the \"Data Submission\"). In the event that such Data Submission is requested by a Regulatory Authority, the Responsible Party, as determined by the JRDC, shall be responsible for its preparation and submission.",
    "contradiction_score": 0.010407487861812115,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 235,
    "start_char": 108028,
    "end_char": 108453,
    "original": "(d) Development Plan Amendments . From time to time during the Term, the JRDC shall prepare amendments, as appropriate, to the then-current Development Plan. Subject to the foregoing, the JRDC shall have the right to approve amendments to the Development Plan, with final decision-making authority as provided in Section 2.10. Once approved by the JRDC, such amended Development Plan shall replace the prior Development Plan.",
    "ollama_generated": "(d) Modifications to Development Plan. Throughout the Term, it is understood that the JRDC may propose modifications to the existing Development Plan. However, any proposed changes must be reviewed and ultimately approved by the parties involved, in accordance with Section 2.10. Once the proposed modifications are unanimously agreed upon and approved by all parties, the modified Development Plan shall supersede and replace the previous version of the Development Plan. This provision does not restrict the JRDC from preparing additional or alternative development plans without prior approval, but any such plan would remain inoperative until it has been duly reviewed, amended as necessary, and approved by all parties involved.",
    "contradiction_score": 0.03828482702374458,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 238,
    "start_char": 108994,
    "end_char": 109579,
    "original": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 (b) The Development Plan shall address the conduct of any Clinical Trial for a Combination Therapy and shall (i) specify which Party will be responsible for each activity for the Development of such Combination Therapy and (ii) specify which Party will be responsible for obtaining supplies of the Product or other product in such Combination Therapy as necessary. The JRDC shall review and approve the terms of any agreement with a Third Party in connection with any supply or other aspect of Development of such Combination Therapy.",
    "ollama_generated": "Clause:\nSource: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 (b) The Development Plan shall outline the procedures for any Clinical Trial involving Combination Therapy and shall detail (i) the manner in which responsibilities for each activity pertaining to the Development of such Combination Therapy are to be shared between the Parties, and (ii) the process by which supplies of the Product or other components in such Combination Therapy may be acquired. It is understood that either Party has the autonomy to engage with Third Parties for supply or development aspects of such Combination Therapy, subject to prior consultation with the JRDC for approval of the terms of any relevant agreement.",
    "contradiction_score": 0.21299493312835693,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 240,
    "start_char": 109771,
    "end_char": 109794,
    "original": "5.5 Development Costs .",
    "ollama_generated": "5.5 Shared Development Expenses .\n\nIn this agreement, each Party agrees to share equally any costs incurred during the development phase of the Project, unless otherwise specified in writing by either Party. In such cases where additional expenses are agreed upon, both Parties shall be responsible for their respective portions and will make timely payments. However, should one Party fail to meet their financial obligations in a timely manner, the other Party may elect to cover the delayed costs on behalf of the defaulting Party, with the expectation of reimbursement at the earliest opportunity. This provision does not require either Party to cover development expenses incurred prior to the commencement of this agreement or any future costs associated with the maintenance and operation of the completed Project.",
    "contradiction_score": 0.33797919750213623,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 243,
    "start_char": 111146,
    "end_char": 111742,
    "original": "(a) RevMed or its Affiliates may propose to the JRDC that the Parties conduct a Clinical Trial of a Product in the Field that is not included in the Development Plan for such Product, in which case RevMed shall present the proposed design and projected costs of such Clinical Trial to the JRDC. If Sanofi agrees to include such Clinical Trial and related costs in the Development Plan and Development Budget for such Product, the Parties shall prepare an updated Development Plan and Development Budget and such Clinical Trial shall become part of the Collaboration and subject to this Agreement.",
    "ollama_generated": "(a) The JRDC has the right, but not obligation, to consider a proposal from RevMed or its Affiliates for a Clinical Trial of a Product outside the existing Development Plan for that Product. If RevMed submits such a proposal, including the proposed design and estimated costs, and the JRDC agrees to include this trial in the Product's Development Plan and Budget, then both parties will collaborate to update these documents accordingly. In this instance, the Clinical Trial would become an integral part of the Collaboration, subject to the terms of this Agreement, with RevMed assuming primary responsibility for its execution and associated costs.",
    "contradiction_score": 0.012285735458135605,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 245,
    "start_char": 113264,
    "end_char": 113567,
    "original": "A. Sanofi shall have rights to use, at no additional cost, any RevMed Study Data in its performance of its obligations and exercise of its rights under the Collaboration except in connection with filing of MAAs for the Indication and Product Treatment Regimen that were the subject of such RevMed Study.",
    "ollama_generated": "B. In the course of fulfilling its obligations and exercising its rights under the Collaboration, RevMed retains the right to use any Study Data generated without incurring additional costs; however, this right is limited when it comes to the filing of MAAs for the Indication and Product Treatment Regimen that were the subject of the said RevMed Study. The responsibility for these specific MAA filings remains solely with Sanofi.",
    "contradiction_score": 0.21480675041675568,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 246,
    "start_char": 113567,
    "end_char": 114294,
    "original": "B. If Sanofi wishes to use, or actually uses, RevMed Study Data in support of filing a MAA for the Indication and Product Treatment Regimen that were the subject of such RevMed Study, it shall notify RevMed in writing and shall make a buy-in  payment to RevMed in Dollars equal to [***] within [***] after the date that Sanofi receives a detailed invoice from RevMed setting forth [***]. In such case the RevMed Study shall be deemed a Clinical Trial under the Collaboration for all purposes, including that all Know-How  conceived, reduced to practice, developed, made or otherwise generated by or on behalf of RevMed or its Affiliates in the course of the RevMed Study activities shall be deemed Program Inventions hereunder.",
    "ollama_generated": "A. Upon Sanofi's decision to utilize, or actual utilization, RevMed Study Data for the purpose of submitting a MAA for the Indication and Product Treatment Regimen derived from such RevMed Study, Sanofi shall provide written notice to RevMed and make a buy-in payment to RevMed in Dollars equivalent to [***] within [***] following Sanofi's receipt of an invoice from RevMed outlining the specifics. In this scenario, the RevMed Study will be considered a Clinical Trial under the Collaboration for all purposes, including the understanding that any Know-How conceived, reduced to practice, developed, made or otherwise generated by or on behalf of RevMed or its Affiliates during the RevMed Study activities shall be deemed Program Inventions. However, it is important to note that this does not imply an obligation for Sanofi to exercise such rights or pursue commercialization unless mutually agreed upon by both parties.",
    "contradiction_score": 0.0014283417258411646,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 255,
    "start_char": 118476,
    "end_char": 118748,
    "original": "6.3 Cooperation . For each Product, each Party shall cooperate reasonably with the other Party with respect to all regulatory activities under the Research Plan or Development Plans relating to the Products. Without limiting the foregoing, for such activities, each Party:",
    "ollama_generated": "6.3 Collaboration. In regard to each Product, each Party shall make a good faith effort to collaborate with the other Party concerning all regulatory activities under the Research Plan or Development Plans associated with the Products. Notwithstanding the above, for these activities, neither Party is obligated to take extraordinary measures beyond their practical capabilities or resources; instead, they will use reasonable discretion in their cooperation. Each Party reserves the right to independently assess and make decisions regarding compliance with applicable regulations related to the Products.",
    "contradiction_score": 0.012633342295885086,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 257,
    "start_char": 120782,
    "end_char": 121220,
    "original": "If any Regulatory Material to be provided under this Section 6.3 was originally created in a language other than the English language, if requested by the receiving Party, the providing Party shall provide an English translation along with the original document to the receiving Party at the receiving Party\u2019s cost if such translation would not normally be made by the providing Party in accordance with its standard operating procedures.",
    "ollama_generated": "If any Regulatory Material provided under this Section 6.3 was initially prepared in a language other than English, it shall be the exclusive responsibility of the receiving Party to bear the costs associated with obtaining an English translation of such material, unless the providing Party routinely provides translations as part of its standard operating procedures. However, the providing Party will cooperate and facilitate the provision of the English translation upon the reasonable request of the receiving Party. The original document shall also be provided concurrently.",
    "contradiction_score": 0.18672418594360352,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 263,
    "start_char": 126525,
    "end_char": 127572,
    "original": "6.9 Audit Vendors  & Contractors . Each Party shall have in place standard operating procedures for their vendor management processes (including with respect to compliance). Each Party shall notify the other Party of any inspections of such Party or any of its Affiliates or subcontractors conducted by any Regulatory Authority or other government entity and any related findings to the extent that such inspections relate to the activities conducted hereunder. In addition, Sanofi shall have the right to conduct customary reviews and audits of RevMed and its Affiliates and subcontractors (provided that, with respect to Permitted Contractors or Researchers that Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 RevMed entered into a written agreements with prior to the Effective Date, such right of Sanofi shall be to the extent RevMed has the right to permit Sanofi to do so under such written agreements, and provided further, that RevMed shall use Commercially Reasonable Efforts to secure such right for Sanofi where one does not exist).",
    "ollama_generated": "6.9 Vendor and Contractor Audits. Each Party is encouraged, though not strictly obligated, to maintain standard operating procedures for their vendor management processes, including compliance-related measures. Each Party shall voluntarily inform the other Party of any inspections conducted by Regulatory Authorities or government entities on themselves, their Affiliates, or subcontractors pertaining to activities under this agreement, as well as any findings relevant to those activities. Additionally, Sanofi reserves the option to perform customary reviews and audits on RevMed and its Affiliates and subcontractors (with the exception that Sanofi's right to do so is contingent upon RevMed having granted such permission in written agreements with Permitted Contractors or Researchers prior to the Effective Date, and furthermore, Sanofi's ability to conduct these audits may be restricted where RevMed does not possess the power to grant such permission under those existing agreements. In such cases, Sanofi will make reasonable efforts to secure this right from RevMed where it is absent.)",
    "contradiction_score": 0.002113549504429102,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 264,
    "start_char": 127599,
    "end_char": 127611,
    "original": "Article VII.",
    "ollama_generated": "Article VII (Alternative Performance)\n\nIn the event that the obligor fails to fulfill its obligations under this Agreement within the specified timeframe, the non-obligor shall have the right, but not the obligation, to engage a third party to perform said duties, at the expense of the obligor. If the obligor disputes the necessity or sufficiency of such performance by a third party, it shall bear the costs associated with such challenge and any resulting delay in the fulfillment of its obligations. In the event that the obligor successfully demonstrates that the third-party performance was unnecessary or insufficient, the non-obligor shall reimburse the obligor for all reasonable expenses incurred in connection with the challenge.",
    "contradiction_score": 0.11484376341104507,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 265,
    "start_char": 127611,
    "end_char": 128295,
    "original": "MANUFACTURING AND SUPPLY 7.1 General . The Manufacture of the SHP2 Inhibitors and Products, including all process and formulation development in connection therewith, including Chemistry, Manufacturing and Controls (CMC) activities, shall be overseen and coordinated by (a) RevMed for clinical supply related to Phase 1 Clinical Trials, and Phase 2 Clinical Trials that are not Registrational Clinical Trials, and (b) Sanofi for supply of all Clinical Trials other than those set forth in clause (a) and all supply associated with Commercialization. If requested by the JMC, each Party shall provide reports summarizing its Manufacturing activities and the results of such activities.",
    "modified": "MANUFACTURING AND SUPPLY 7.1 Modified . Responsibility for the Manufacture of the SHP2 Inhibitors and Products, including all process and formulation development in connection therewith, including Chemistry, Manufacturing and Controls (CMC) activities, will be shared by both Parties, with RevMed leading for clinical supply related to Phase 1 Clinical Trials, Phase 2 Clinical Trials that are not Registrational Clinical Trials, and Sanofi taking the lead for all other Clinical Trial supplies and Commercialization. Each Party shall maintain records of its Manufacturing activities and shall provide reports summarizing such activities upon request by the JMC. In case of any disagreement or need for coordination, the Joint Management Committee (JMC) will oversee and make decisions regarding the manufacturing process.",
    "contradiction_score": 0.5345863699913025,
    "kept": true
  },
  {
    "clause_index": 266,
    "start_char": 128295,
    "end_char": 129726,
    "original": "7.2 Transfer of Manufacturing Know-How . Upon Sanofi\u2019s request, RevMed shall transfer to Sanofi or its designee Know-How  Controlled by RevMed that is necessary or useful to enable the Manufacture of each SHP2 Inhibitor that is nominated or designated as a Development Candidate pursuant to Section 4.3, Development Candidate and Product, including regulatory starting materials and key starting materials, as set forth in this Section 7.2. Sanofi may also request such Know-How  for backup SHP2 Inhibitors that Sanofi is considering for nomination or designation as a Development Candidate, and RevMed shall transfer such Know-How  to Sanofi (to the extent any exists). RevMed shall (a) at [***] cost, provide copies or samples of relevant documentation (including, but not limited to, documentation listed in Exhibit K  of the Correspondence), materials and other embodiments of such Know-How,  (b) at [***] cost (calculated on [***]), make available RevMed\u2019s qualified technical employees, and use Commercially Reasonable Efforts to make available the qualified technical personnel of RevMed\u2019s independent manufacturing contractors, in each case, on a reasonable basis to consult with Sanofi or its designee with respect to such Know-How,  and (c) if requested by Sanofi, at [***] cost, use Commercially Reasonable Efforts to support Sanofi in the establishment of its own supply agreements with Third Party suppliers of RevMed.",
    "ollama_generated": "7.2 Knowledge Transfer Obligations of RevMed: Upon request from Sanofi, RevMed shall make available to Sanofi or its designated representative any proprietary knowledge (Know-How) controlled by RevMed that is essential or beneficial for the production of each SHP2 Inhibitor nominated or selected as a Development Candidate in accordance with Section 4.3, Development Candidate and Product. This includes regulatory starting materials and key starting materials, as outlined in this Section 7.2. Sanofi may also request such Know-How for potential additional SHP2 Inhibitors they are considering for nomination as Development Candidates, and RevMed shall provide this information to Sanofi (to the extent it is available).\n\nRevMed will:\n(a) at its own expense, supply copies or samples of relevant documentation (such as those listed in Exhibit K of the Correspondence), materials, and other embodiments of the Know-How;\n(b) at its own expense (calculated on [***]), make available RevMed's qualified technical staff for consultation with Sanofi or its designated representative regarding the Know-How; and\n(c) if requested by Sanofi, at its own expense, provide reasonable efforts to aid Sanofi in negotiating and establishing its own supply agreements with third-party vendors who previously supplied RevMed. However, it is clarified that this obligation does not extend to any legal or binding commitments on the part of RevMed.\n\nThis revised clause shifts the responsibility for the establishment of supply agreements from Sanofi to RevMed, and reduces the specificity in the cost calculations, making them more flexible.",
    "contradiction_score": 0.006475944072008133,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 268,
    "start_char": 130171,
    "end_char": 130481,
    "original": "Such Supply Agreement shall cover the documentation and other quality requirements for the acceptance of previously manufactured supply of Product for use by the other Party. The price charged by the manufacturing Party under any Supply Agreement shall be equal to [***] unless otherwise agreed by the Parties.",
    "ollama_generated": "This Supply Agreement shall encompass the specifications and quality standards for the acceptance of pre-existing supply of Product, suitable for use by the counterparty. The price levied by the manufacturing Party in any Supply Agreement will be [***], unless a different rate is mutually agreed upon by both Parties in writing. However, it should be noted that the responsibility to negotiate and agree on pricing modifications falls solely upon the Parties themselves.",
    "contradiction_score": 0.0019376338459551334,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 271,
    "start_char": 131500,
    "end_char": 132636,
    "original": "8.2 Commercialization Plan . Promptly after the formation of the JCC, Sanofi shall prepare and provide to the JCC for review and discussion a written plan for the Commercialization of such Product in the Licensed Territory (the \u201c Commercialization Plan \u201d). Each Commercialization Plan shall include a reasonably detailed description of (a) [***]\u037e (e) non-binding  sales and marketing forecasts in the U.S.\u037e (f) non-binding  net sales projections in the U.S.\u037e (g) [***]\u037e (h) non-binding  sales and marketing forecasts and non-binding  net sales projections, in each case, outside of the U.S. (i) [***], and in such case the Parties shall amend the Profit/Loss Share Agreement accordingly. Sanofi shall periodically (at least [***]) prepare updates and amendments to its Commercialization Plan to reflect changes in its plans, including in response to changes in the marketplace, relative success of the Products and other relevant factors influencing such plans and activities. Sanofi shall submit all updates and amendments to each Commercialization Plan to the JCC for review and discussion before adopting such updates and amendments.",
    "ollama_generated": "8.2 Commercialization Strategy: Upon formation of the JCC, Partner A (Sanofi) may choose, at its sole discretion and convenience, to prepare a written strategy for the Marketing and Sales of the Product within the Licensed Territory (the \"Commercial Strategy\"). This strategy shall contain, but not be limited to, a general overview of (a) [***]; (e) tentative, non-binding sales and marketing predictions in the U.S.; (f) tentative, non-binding net revenue estimates in the U.S.; (g) [***]; (h) tentative, non-binding sales and marketing predictions and net revenue estimates, for each case, outside of the U.S.; (i) [***]. In the event that Partner A decides to implement such a Commercial Strategy, the Parties shall adjust the Profit/Loss Share Agreement accordingly.\n\nPartner A shall be permitted, although not obligated, to periodically update and amend its Commercial Strategy to accommodate changes in market conditions, product performance, or other relevant factors impacting these plans and activities. Such updates and amendments do not require JCC review unless Partner A deems it necessary for the updated strategy's success.",
    "contradiction_score": 0.02111935243010521,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 274,
    "start_char": 133862,
    "end_char": 134110,
    "original": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 8.5 Patent Marking . Each Party shall mark all Products in accordance with the applicable patent marking laws, and shall require all of its Affiliates, Sublicensees and Distributors to do the same.",
    "modified": "Altered Clause:\n\nIn light of REVOLUTION MEDICINES, INC., S-1, 1/17/2020: 8.5 Patent Labeling Conformance\n\nEach Party is encouraged but not obligated to comply with the applicable patent marking laws and may choose whether or not to label its Products accordingly. However, it is recommended that all such efforts are passed down to Affiliates, Sublicensees, and Distributors as part of a best-practice protocol.",
    "contradiction_score": 0.6623426675796509,
    "kept": true
  },
  {
    "clause_index": 275,
    "start_char": 134110,
    "end_char": 134602,
    "original": "8.6 Reports . Each Party shall update the JCC at each regularly scheduled JCC meeting regarding its Commercialization activities with respect to the Products. Each such update shall be in a form to be agreed by the JCC by mutual agreement of its representatives (without application of any final decision-making right of either Party) and shall summarize such Party\u2019s (either by itself or through its Affiliates and its Sublicensees) Commercialization activities with respect to the Products.",
    "ollama_generated": "8.6 Reports and Updates: The Parties have the discretionary power, but not the obligation, to provide updates on their Commercialization activities related to the Products at each regularly scheduled JCC meeting. These updates, if provided, shall be in a mutually agreed-upon format and will summarize the Commercialization activities of each Party (either independently or through its Affiliates or Sublicensees) with respect to the Products. No final decision-making authority is held by either Party in determining the format for these updates.",
    "contradiction_score": 0.023699291050434113,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 282,
    "start_char": 137573,
    "end_char": 138536,
    "original": "9.2 Milestone Payments . Upon first achievement of a milestone event described below in this Section 9.2 (a \u201c Milestone Event \u201d) by Sanofi or any of its Affiliates or Sublicensees, Sanofi shall notify RevMed of such achievement and RevMed will issue an invoice to Sanofi for the corresponding one- time,  non-refundable  and non-creditable  milestone payment (a \u201c Milestone Payment \u201d). RevMed will also have the right to notify Sanofi in writing if RevMed believes a Milestone Event has been achieved even if Sanofi has not provided such notice to RevMed, and unless Sanofi notifies RevMed within [***] Business Days after receipt of such notice from RevMed that such Milestone Event has not been achieved, RevMed may issue an invoice to Sanofi for the corresponding Milestone Payment. Subject to the terms and conditions of this Agreement, Sanofi will pay to RevMed the following Milestone Payments within [***] after receipt of such invoice therefor as follows:",
    "modified": "9.2 Milestone Payments. In the event that Sanofi or any of its Affiliates or Sublicensees fails to achieve a milestone event described below in this Section 9.2 (a \u201cMilestone Non-Event\u201d), Sanofi will be obligated to notify RevMed of such non-achievement and may be liable for the corresponding one-time, non-refundable, and non-creditable milestone payment (a \"Milestone Payment\"). Sanofi shall have the right to contest a Milestone Non-Event in writing if it believes that a Milestone Event has not been achieved, and unless RevMed notifies Sanofi within [***] Business Days after receipt of such notice from Sanofi that a Milestone Event has been achieved, Sanofi may avoid payment of the corresponding Milestone Payment. Subject to the terms and conditions of this Agreement, RevMed will not issue an invoice to Sanofi for any Milestone Payments until [***] after receipt of such evidence of non-achievement from Sanofi.",
    "contradiction_score": 0.9081578850746155,
    "kept": true
  },
  {
    "clause_index": 289,
    "start_char": 141229,
    "end_char": 141253,
    "original": "(c) Royalty Reductions .",
    "ollama_generated": "(c) Adjustable Royalties Modification.\n\nUpon the occurrence of any event that may impact the Seller's cost structure or profitability, the Buyer shall have the discretionary power to adjust the royalty rate payable by the Buyer, subject to a minimum threshold and with prior written notice to the Seller. The burden of proof for such an adjustment rests solely on the Buyer. In no event shall this provision be interpreted to release the Buyer from its obligation to make any royalties payments altogether.",
    "contradiction_score": 0.03457234427332878,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 290,
    "start_char": 141253,
    "end_char": 141621,
    "original": "(i) In any country in which there is no Valid Claim and no Regulatory Exclusivity for such Product, at the time of sale of such Product in such country during the applicable Royalty Term, Sanofi\u2019s obligation to pay royalties under Section 9.3(a) on Net Sales of such Product in such country shall be reduced to [***]% of the rates otherwise payable under such section.",
    "modified": "(j) In any nation where there exists neither a Valid Claim nor Regulatory Exclusivity pertaining to that Product, during the course of product sales in said country within the applicable Royalty Term, the duty of Sanofi to remit royalties as per Section 9.3(a) on Net Sales of such Product in that country will be increased to [***] times the standard rates stated under such section.",
    "contradiction_score": 0.9740937352180481,
    "kept": true
  },
  {
    "clause_index": 305,
    "start_char": 151226,
    "end_char": 151964,
    "original": "(b) Value Added Tax.  Notwithstanding anything contained in Section 9.7(a), this Section 9.7(b) will apply with respect to value added tax (or sales, use or indirect tax) (\u201cVAT\u201d). All payments to be made by Sanofi hereunder are exclusive of VAT. If any VAT is chargeable in respect of any such payments, Sanofi will notify RevMed and pay VAT at the applicable rate in respect of any such payments following the receipt of a VAT invoice in the appropriate form issued by RevMed in respect of those payments or Sanofi shall self-assess and pay such VAT, such VAT to be payable on the later of the due date of the payment to which such VAT relates and [***] after the receipt by Sanofi of the applicable invoice relating to that VAT payment.",
    "modified": "(b) Value Added Tax. Contrary to Section 9.7(a), this Section 9.7(b) shall govern value added tax (or sales, use or indirect tax) (\u201cVAT\u201d). All payments made by RevMed hereunder shall include VAT. If no VAT is chargeable in respect of any such payments, Sanofi will not be required to pay any VAT. However, if RevMed is entitled to recover VAT on any such payments, Sanofi shall reimburse RevMed for the VAT amount at the applicable rate, with such reimbursement due upon the receipt of a valid VAT invoice issued by Sanofi and within 30 days after the receipt of said invoice.",
    "contradiction_score": 0.7787050008773804,
    "kept": true
  },
  {
    "clause_index": 316,
    "start_char": 157073,
    "end_char": 157614,
    "original": "(c) Each Party shall promptly disclose to the other Party in writing and shall cause its Affiliates, and its and their Sublicensees to so disclose, any Joint Program Know-How  and any other Program Inventions. Each Party shall also respond promptly to reasonable requests from the other Party for additional information relating to such Joint Program Know-How  and other Program Inventions as reasonably necessary to exercise such Party\u2019s rights and perform its obligations, hereunder and under any Ancillary Agreement, with respect thereto.",
    "modified": "(c) Each Party shall not be obligated to disclose in writing or cause their Affiliates or Sublicensees to disclose Joint Program Know-How or any other Program Inventions until a written request is made by the other Party. Once such a request is made, the receiving Party shall respond within a reasonable timeframe, providing the requested information necessary for the requesting Party to exercise its rights and fulfill its obligations hereunder and under any Ancillary Agreement, with respect thereto, to the extent that the disclosure does not conflict with any legal or contractual confidentiality obligations.",
    "contradiction_score": 0.7073788642883301,
    "kept": true
  },
  {
    "clause_index": 321,
    "start_char": 159729,
    "end_char": 160483,
    "original": "10.3 CREATE Act . Notwithstanding anything to the contrary in this Article X, each Party shall have the right to invoke the Cooperative Research and Technology Enhancement Act of 2005, 35 U.S.C. \u00a7102(c) (the \u201c CREATE Act \u201d) when exercising its rights under this Article X without the prior written consent of the other Party. Where such Party intends to invoke the CREATE Act, as permitted by the preceding sentence, it shall notify the other Party and the other Party shall cooperate and coordinate its activities with the Party invoking the CREATE Act with respect to any submissions, filings or other activities in support thereof. The Parties acknowledge and agree that this Agreement is a \u201cjoint research agreement\u201d as defined in 35 U.S.C. \u00a7 100(h).",
    "ollama_generated": "10.3 CREATE Act Exception Clause. Contrary to any provisions in Article X, neither Party requires the prior written consent of the other to utilize the Cooperative Research and Technology Enhancement Act of 2005, 35 U.S.C. \u00a7102(c) (hereinafter \"CREATE Act\") while exercising their rights under Article X. If a Party chooses to employ the CREATE Act, they are obligated to inform the other Party. Upon notification, the non-invoking Party shall make reasonable efforts to collaborate and coordinate activities with the invoking Party regarding any submissions, filings, or other actions related thereto. The Parties mutually understand and accept that this Agreement is characterized as a \"joint research agreement\" as defined in 35 U.S.C. \u00a7 100(h). However, it's essential to note that the lack of prior written consent does not imply an obligation for either Party to cooperate or coordinate beyond the reasonable efforts described above.",
    "contradiction_score": 0.24589788913726807,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 331,
    "start_char": 165376,
    "end_char": 165724,
    "original": "(c) Domain Names . Sanofi shall have the sole right to register and shall own and control any domain names for the Product Marks that it registers in any generic Top Level Domain (e.g., .com, .info, .net or .org) or in any country code Top Level Domain for any country in the Licensed Territory (e.g., .us for the United States and .ca for Canada).",
    "ollama_generated": "(c) Domain Names . The Licensor grants exclusive rights to Sanofi for registration of domain names associated with the Product Marks within any generic Top Level Domains (e.g., .com, .info, .net or .org) and in any country code Top Level Domains for countries within the Licensed Territory (e.g., .us for the United States and .ca for Canada). Sanofi shall be responsible for maintaining ownership and control of these registered domain names; however, the Licensor retains the right to request transfer or termination of such domain names upon reasonable notice, in which case Sanofi will cooperate diligently.",
    "contradiction_score": 0.013541966676712036,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 336,
    "start_char": 166608,
    "end_char": 167312,
    "original": "(a) If either Party reasonably determines, in consultation with the JRDC, that (i) the Research, Development, Manufacture, or Commercialization of [***] infringes or misappropriates any Patent Right or other intellectual property right of a Third Party, such that such Party or its respective Affiliates or Sublicensees cannot [***] without infringing or misappropriating the Patent Right or other intellectual property right of such Third Party (a \u201c Third Party Right \u201d) or (ii) [***], such Party shall notify the other Party (such notification, the \u201c Third Party Right Notification \u201d), and promptly thereafter the Parties shall discuss obtaining a license to the applicable intellectual property right.",
    "ollama_generated": "(a) In the event that either Party, in consultation with the JRDC, ascertains that the Research, Development, Manufacture, or Commercialization of [***] potentially violates any Patent Right or other intellectual property right belonging to a Third Party (hereafter referred to as \"Potential Third Party Right\"), such that it might impede either Party, its Affiliates, or Sublicensees from performing their intended activities without breaching the Patent Right or other intellectual property right of the said Third Party, such Party shall provide notice to the other Party (this notification is hereafter referred to as \"Potential Third Party Right Notification\"). Upon receipt of the Potential Third Party Right Notification, both Parties will collaborate diligently and promptly to explore and negotiate, in good faith, the possibility of acquiring a license for the applicable intellectual property right, with the ultimate aim of mitigating any potential infringement or misappropriation. However, the obligation to obtain a license will not be considered an admission of wrongdoing or liability on the part of either Party and shall not constitute a waiver of any defenses available under applicable law.",
    "contradiction_score": 0.008289843797683716,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 337,
    "start_char": 167312,
    "end_char": 168297,
    "original": "(b) Sanofi shall have the first right, but not the obligation, through counsel of its choosing, to negotiate and obtain a license with respect to such Third Party intellectual property right and shall provide RevMed with a copy of such license if it obtains such a license (to the extent permitted by the terms of such license, provided that Sanofi shall use Commercially Reasonable Efforts to obtain such permission to provide such copy). If Sanofi elects not to obtain such license, or fails to obtain such license within [***] after the Third Party Right Notification, then RevMed shall have the right to obtain such license, with the right to grant the corresponding sublicense to Sanofi pursuant to Section 10.7(c). The Party negotiating a license shall keep the other Party reasonably informed of the material terms for such prospective license applicable to the Products and shall consider in good faith the comments of such other Party with respect to such Third Party license.",
    "ollama_generated": "(b) RevMed grants Sanofi the preference, without obligation, through counsel of its choosing, to negotiate and acquire a license pertaining to any relevant Third Party intellectual property right. If Sanofi exercises this option, they will provide RevMed with a copy of such license (subject to the terms of said license, upon Sanofi's successful acquisition of permission to share such information). Should Sanofi opt not to pursue or fail to secure such license within [***] following the Third Party Right Notification, RevMed retains the authority to negotiate and procure the license. Upon doing so, RevMed may extend a sublicense to Sanofi under Section 10.7(c), subject to their discretion. The party engaged in licensing discussions is required to maintain regular communication with the other party concerning the material terms of the prospective license, and shall take into account the other party's views regarding the Third Party license, acting in good faith during these negotiations.",
    "contradiction_score": 0.26513323187828064,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 354,
    "start_char": 184437,
    "end_char": 184881,
    "original": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 11.8 Permitted Disclosure for CREATE Act . In order for a Party to exercise its rights under Section 10.3, such Party shall be allowed to disclose in a patent application it prepares and files pursuant to this Agreement the names of the Parties to this Agreement, or amends a pending application it is prosecuting pursuant to this Agreement to state the names of the Parties to this Agreement.",
    "ollama_generated": "Clause:\nREVOLUTION MEDICINES, INC., S-1, 1/17/2020 - 11.8 Disclosure under CREATE Act Permitted Disclosure. For the purpose of exercising rights as per Section 10.3, a Party shall have the right to disclose in a patent application it prepares and files or amends a pending application it is prosecuting, not only the names of the Parties to this Agreement, but also any information that may be reasonably required for such application or amendment, provided such disclosure is consistent with the terms of this Agreement. The Party shall, however, bear sole responsibility for ensuring compliance with all applicable laws and regulations in connection with such disclosures.",
    "contradiction_score": 0.006893983110785484,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 357,
    "start_char": 185260,
    "end_char": 185278,
    "original": "12.2 Termination .",
    "ollama_generated": "12.2 Right to Suspend Services.\n\nUpon written notice, either Party shall have the right, at its sole discretion, to temporarily suspend the provision of services by the other Party if: a) The receiving Party is in material breach of any term or condition under this Agreement and fails to remedy such breach within 30 days of receipt of notice specifying the breach; b) A force majeure event occurs that makes it impossible for the suspending Party to perform its obligations under this Agreement. In either case, the suspending Party shall use reasonable efforts to resume services as soon as practicable after the cause of the suspension has been remedied. The receiving Party shall not be liable for any damages resulting from the exercise of this right, but shall remain obligated to pay all fees accrued prior to the suspension.",
    "contradiction_score": 0.04653351381421089,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 368,
    "start_char": 191762,
    "end_char": 191805,
    "original": "12.3 Effects of Expiration or Termination .",
    "ollama_generated": "12.3 Consequences Arising from Cessation or Lapse:\n\nUpon the cessation or lapse of this Agreement for any reason whatsoever, each party shall promptly discontinue the use of all Confidential Information received hereunder and shall take reasonable measures to ensure that such information is no longer accessible or in the possession of any third party. However, neither party shall have any further obligations or liabilities to the other under this Agreement following its termination, except for the obligations under Sections 12.4 (Obligations Surviving Termination) and 13 (Dispute Resolution).",
    "contradiction_score": 0.059017155319452286,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 369,
    "start_char": 191805,
    "end_char": 192288,
    "original": "(a) General . Upon termination or expiration of this Agreement with respect to any particular Product or country, all rights and obligations of the Parties under this Agreement with respect to such Product or country shall cease except as otherwise set forth in this Section 12.3 or elsewhere in this Agreement, but, for clarity, such termination or expiration shall not affect the Parties\u2019 rights and obligations under this Agreement with respect to the other Products or countries.",
    "ollama_generated": "(a) General. Upon the conclusion or lapse of this Agreement pertaining to a specific Product or region, all rights and duties binding the Parties concerning that particular Product or territory shall be terminated, unless specified in Section 12.3 or other parts of this Agreement; however, it is important to note that such termination or expiration shall not invalidate the Parties' rights and responsibilities under this Agreement regarding any other Products or territories.\n\nIn this revised version, the obligations and rights cease specifically for the Product or country in question upon termination or expiration, but they remain intact for all other Products or regions. This modification creates a more nuanced interpretation, emphasizing that the termination or expiration affects only certain aspects of the agreement, not the entirety.",
    "contradiction_score": 0.004474829416722059,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 377,
    "start_char": 194043,
    "end_char": 194449,
    "original": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 3. Sanofi License to Practice Certain Combinations . [***] RevMed shall, effective upon any such termination of this Agreement, and hereby does, grant to Sanofi [***], under [***], and [***]. For the avoidance of doubt, [***] licensed under this Section 12.3(c)(ii)(A)(3) do not [***]. If Sanofi [***], Sanofi shall so notify RevMed in writing, and [***].",
    "ollama_generated": "Clause:\nSource: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 3. Sanofi License to Practice Certain Combinations . [***] In the event of any termination of this Agreement, RevMed shall immediately cease, and hereby does cease, granting to Sanofi [***], under [***], and [***]. For the avoidance of doubt, the licenses granted under this Section 12.3(c)(ii)(A)(3) by RevMed to Sanofi will terminate upon such termination. If Sanofi continues to practice with these licensed combinations after receiving written notice from RevMed of license termination, Sanofi shall be solely responsible for any infringements or breaches of this Agreement.",
    "contradiction_score": 0.1869049072265625,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 380,
    "start_char": 197541,
    "end_char": 198777,
    "original": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 (iii) Inventory Sell-Off  Period . In the case of a termination of this Agreement, Sanofi (with respect to the Termination Products in the Licensed Territory), shall be entitled, for a period of [***] after termination, to (i) complete Manufacture of work-in-progress,  and (ii) continue conducting Commercialization activities being conducted by Sanofi hereunder as of such termination (if applicable, with respect to the terminated country(ies)), to the extent related to such Termination Product in Sanofi\u2019s inventory as of such termination (or added to such inventory as a result of the completion described in clause (i)), provided that Sanofi fulfills its payment obligations under this Agreement in connection with such inventory sell-off,  provided further that the sharing of Net Profits and Net Losses under the Profit/Loss Share Agreement shall continue to apply during the sell-off  period. For clarity, from and after the expiration of such [***] period all rights and licenses granted to Sanofi hereunder (if applicable, with respect to the terminated country(ies)) shall terminate (except as necessary to permit Sanofi to perform its obligations under this Article XII).",
    "ollama_generated": "Clause:\nSource: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 (iii) Inventory Wind-Down Period. Upon termination of this Agreement by either party, Revolution Medicines, Inc. (with respect to the Termination Products in the Licensed Territory), shall be obligated, for a period of [***] following termination, to:\n\n1. Complete Manufacture of any work-in-progress.\n2. Permit Sanofi to continue conducting Commercialization activities related to the Termination Product as outlined herein (if applicable, in relation to the terminated country(ies)), up until the exhaustion of the inventory stock of such product on hand at the time of termination or any additional inventory produced due to the completion described in clause (i). This permission is contingent upon Revolution Medicines, Inc.'s fulfillment of its payment obligations under this Agreement during the wind-down period.\n3. Continue sharing Net Profits and Net Losses as per the Profit/Loss Share Agreement throughout the wind-down period.\n4. For clarity, from the expiration of such [***] period, all rights and licenses granted to Revolution Medicines, Inc. (if applicable, in relation to the terminated country(ies)) shall be automatically revoked (except as necessary for Revolution Medicines, Inc. to meet its obligations under this Article XII).",
    "contradiction_score": 0.33971232175827026,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 385,
    "start_char": 202073,
    "end_char": 202992,
    "original": "B. To the extent Sanofi has the right to do so, Sanofi shall promptly provide RevMed with a copy (which may be redacted in Sanofi\u2019s discretion if required to protect confidential information of Sanofi or a Third Party) of each license agreement, collaboration agreement or vendor agreement then effective between Sanofi (or its Affiliates) and a Third Party that exclusively relates to any Termination Product, or the Development, Manufacture and Commercialization thereof, and, upon RevMed\u2019s request, to the extent Sanofi has the right to do so, Sanofi shall assign or sublicense, and shall ensure that its Affiliates assign or sublicense, to RevMed any such agreement(s). If Sanofi does not have the right to do so, Sanofi will provide RevMed with contact information for such Third Party so that RevMed may pursue an agreement directly with such licensor, collaborator or vendor with respect to Termination Products.",
    "modified": "A. At Sanofi's discretion, Sanofi may choose not to provide a copy of each license agreement, collaboration agreement, or vendor agreement (which may be redacted to protect confidential information of Sanofi or a Third Party) that exclusively concerns any Termination Product, or the Development, Manufacture, and Commercialization thereof, to RevMed. However, upon RevMed's request, Sanofi will make reasonable efforts, within its rights, to assign or sublicense, and to ensure that its Affiliates do the same, any such agreement(s) to RevMed. If Sanofi is unable to assign or sublicense an agreement due to lack of right, Sanofi will instead provide RevMed with contact information for the relevant Third Party, allowing RevMed to pursue a direct agreement with the licensor, collaborator, or vendor regarding Termination Products.",
    "contradiction_score": 0.848068356513977,
    "kept": true
  },
  {
    "clause_index": 389,
    "start_char": 204904,
    "end_char": 205447,
    "original": "E. If at the time of such termination, RevMed or its Affiliates are not Manufacturing a particular Termination Product, then, at RevMed\u2019s request, Sanofi shall: (1) [***], provided that Sanofi shall in no case be obligated to [***], and provided further that such [***]\u037e and (2) if it has the right to do so, assign or transfer to RevMed any Manufacturing agreement between Sanofi and a Third Party contract manufacturer with respect to such Termination Product\u037e or (3) conduct a technology transfer analogous to that described in Section 7.2.",
    "modified": "F. In the event of termination, if RevMed or its Affiliates are not currently manufacturing the specified Termination Product at the time, then upon RevMed's request, Sanofi shall be required to: (1) [***], with the understanding that Sanofi will bear no responsibility for any costs or expenses incurred during this process, unless explicitly agreed otherwise; and (2) should it have the opportunity, assign or transfer to RevMed any Manufacturing agreements between Sanofi and a Third Party contract manufacturer pertaining to such Termination Product, without any obligation to do so; or (3) perform a technology transfer in accordance with Section 7.2, but only if Sanofi deems it feasible and beneficial for its operations.",
    "contradiction_score": 0.5715650916099548,
    "kept": true
  },
  {
    "clause_index": 400,
    "start_char": 211332,
    "end_char": 212369,
    "original": "12.4 Survival . The following Sections and Articles shall survive the termination or expiration of this Agreement: Articles I (Definitions) (to the extent necessary to give effect to the other Sections and Articles that survive under this Section 12.4) and XV (General Provisions) and Sections 5.8 (Development Records) (for the period stated therein), 9.8 (Records) (for the period stated therein), 11.1 (Duty of Confidence), 11.2 (Exceptions), 11.3 (Authorized Disclosures), 11.5(a) and 11.5(b) (Publicity\u037e Use of Names), 11.6 (Return of Confidential Information), 11.7 (Attorney-Client Privilege), 11.8 (Permitted Disclosures for CREATE Act), 12.3 (Effects of Expiration or Termination), 12.4 (Survival), 12.5 (Accrued Rights and Obligations), 12.6 (Termination Not Sole Remedy), 14.1 (Indemnification by RevMed) (as to activities conducted during the Term), 14.2 (Indemnification by Sanofi) (as to activities conducted during the Term), 14.3 (Indemnification Procedure), 14.4 (Mitigation of Loss), and 14.5 (Limitation of Liability).",
    "ollama_generated": "12.4 Persistence: Upon termination or expiration of this Agreement, the following Sections and Articles shall persist indefinitely unless otherwise specified: Articles I (Definitions) (as necessary for interpreting the surviving provisions), Article XV (General Provisions), Sections 5.8 (Development Records), 9.8 (Records), 11.1 (Duty of Confidence), 11.2 (Exceptions), 11.3 (Authorized Disclosures), 11.5(a) and 11.5(b) (Publicity\u037e Use of Names), 11.6 (Return of Confidential Information), 11.7 (Attorney-Client Privilege), 11.8 (Permitted Disclosures for CREATE Act), 12.3 (Consequences of Expiration or Termination), 12.4 (Persistence), 12.5 (Ongoing Rights and Obligations), 12.6 (Termination Not an Exclusive Remedy), 14.1 (Indemnification by RevMed) (regarding activities throughout the entire duration post-Agreement term), 14.2 (Indemnification by Sanofi) (pertaining to activities throughout the entire duration post-Agreement term), 14.3 (Indemnification Procedure), 14.4 (Mitigation of Loss), and 14.5 (Expanded Liability Limitations).",
    "contradiction_score": 0.43216851353645325,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 411,
    "start_char": 216115,
    "end_char": 223475,
    "original": "(a) RevMed has not had any Affiliates prior to the Execution Date and does not have any Affiliates as of the Execution Date\u037e (b) RevMed is the sole and exclusive owner of all of the RevMed Background Technology, free and clear or all liens and encumbrances, and no Third Party owns or possesses any right, title or interest in or to any of the RevMed Licensed Technology existing as of the Execution Date\u037e (c) RevMed has not previously agreed to or otherwise committed to assign, transfer or convey or otherwise encumber its rights, title and interests in and to RevMed Licensed Technology existing as of the Execution Date\u037e (d) To the Knowledge of RevMed, all Patent Rights owned or Controlled by RevMed, existing as of the Execution Date, and reasonably necessary or useful for conducting the Collaboration or otherwise necessary or useful for Researching, Developing, Manufacturing, Commercializing or otherwise exploiting Product in the Field, including the Development or Manufacture of the Products as contemplated in the initial Research Plan and Development Plan attached to this Agreement as of the Execution Date and Commercialization of the Products, as provided hereunder are listed in Exhibit O  of the Correspondence\u037e (e) RevMed has the right to grant the licenses and other rights expressly granted herein to Sanofi, and it has not granted any license, right or interest in, to or under the RevMed Licensed Technology to any Third Party (or agreed to make any such grant) to exploit SHP2 Inhibitors or Products in the Field\u037e (f) To RevMed\u2019s Knowledge, the research and development of the Development Candidate and use of RevMed Background Know-How  in connection therewith does not infringe the claims of any issued Patent or published patent application of any Third Party\u037e (g) The research and development of the SHP2 Inhibitors and use of RevMed Background Know-How  in connection therewith does not misappropriate the Know-How  of any Third Party\u037e (h) The research and development of SHP2 Inhibitors (including pursuant to the activities set forth in the initial Research Plan and initial Development Plan) does not breach any obligation of confidentiality or non-use  owed by RevMed to a Third Party\u037e (i) To RevMed\u2019s Knowledge, no Third Parties are misappropriating the RevMed Background Know-How  and there are no activities by Third Parties that are infringing the RevMed Background Patents\u037e Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 (j) There are no judgments or settlements against or owed by RevMed, and to RevMed\u2019s Knowledge, there are no pending claims or litigation or written threats of possible claims or litigation, in each case relating to the SHP2 Inhibitors or otherwise to RevMed Background Technology\u037e (k) The issued RevMed Background Patents are valid, enforceable and subsisting, and the pending applications included in the RevMed Background Patents are being prosecuted in accordance with Applicable Law in all material respects, and RevMed has presented all relevant references, documents and information of which it and the inventors are aware to the relevant patent examiners and patent offices that are required to be so submitted under Applicable Law\u037e (l) The RevMed Background Patents have been filed and maintained properly and correctly and all applicable fees have been paid on or before the due date for payment in all material respects\u037e (m) RevMed has not received any written notice alleging that the RevMed Background Patents, existing as of the Execution Date, are or would be invalid or unenforceable or that the applications included in such RevMed Background Patents will not proceed to grant\u037e (n) There (i) are no actual, pending or, to RevMed\u2019s Knowledge, alleged or threatened, adverse actions, suits, claims, interferences, re-examinations, oppositions, inventorship challenges or formal governmental investigations involving the RevMed Background Technology that are in or before any Governmental Authority, and (ii) are no actual, pending or, to RevMed\u2019s Knowledge, alleged or threatened, adverse actions, suits, claims, interferences, re-examinations,  oppositions, inventorship challenges or formal governmental investigations involving the RevMed Licensed Technology\u037e (o) The inventions claimed or covered by the RevMed Licensed Technology (i) were not conceived, discovered, developed or otherwise made in connection with any research activities funded, in whole or in part, by the federal government of the United States or any agency thereof, (ii) are not a \u201csubject invention\u201d as that term is described in 35 U.S.C. \u00a7 201(e), (iii) are not otherwise subject to the provisions of the Patent and Trademark Law Amendments Act of 1980, as amended, codified at 35 U.S.C. \u00a7\u00a7 200-212,  as amended, as well as any regulations promulgated pursuant thereto, including in 37 C.F.R. part 401, and (iv) are not the subject of any licenses, options or other rights of any other Governmental Authority, within or outside the United States, due to such Governmental Authority\u2019s funding of research and development or otherwise (other than the right to receive payments or any law of general application that applies to personal property generally, e.g., takings laws)\u037e (p) None of the RevMed Background Patents are licensed to RevMed from a Third Party\u037e (q) There are no exclusivity provisions or any other restrictions in any agreement between RevMed or its Affiliates, on the one hand, and any Third Party, on the other hand, of any SHP2 Inhibitor or Product, that would limit Sanofi\u2019s ability to exercise its rights under this Agreement\u037e Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 (r) All current and former officers, employees, and consultants of RevMed who are inventors of or have otherwise contributed in a material manner to the creation or development of any RevMed Background Technology have executed and delivered to RevMed an assignment or other agreement regarding the protection of proprietary information and the assignment to RevMed of inventions or work product created or generated in the course of employment by or providing services for RevMed, the current forms of which has been made available for review by Sanofi\u037e (s) The portions of RevMed Background Know-How  that are proprietary to RevMed and unpublished as of the Execution Date and material to Research, Development, Manufacture or Commercialization of SHP2 Inhibitors or Products in the Field have been kept confidential by RevMed and have only been disclosed to Third Parties under obligations of confidentiality, and to the Knowledge of RevMed, no such Third Party has breached any such confidentiality obligation to RevMed\u037e (t) RevMed has included in the electronic dataroom for this Agreement all information in its possession that is material to the Research, Development, Manufacture or Commercialization of the Development Candidate as of the Execution Date, and such information does not contain any untrue statement(s) of fact, or omit to state any fact(s), in either case that are collectively material to the Research, Development, Manufacture or Commercialization of the Development Candidate\u037e and (u) To RevMed\u2019s Knowledge, RevMed and its contractors and consultants have conducted all research and development of the SHP2 Inhibitors and Products in material compliance with all Applicable Laws.",
    "ollama_generated": "(a) As of the Execution Date, RevMed does not have any Affiliates and has not had any Affiliates prior to the Execution Date\u037e (b) All of the RevMed Background Technology is solely and exclusively owned by RevMed, free and clear of all liens and encumbrances, with no Third Party holding any right, title or interest in or to any of the RevMed Licensed Technology as of the Execution Date\u037e (c) Prior to the Execution Date, RevMed has not agreed, committed or otherwise conveyed its rights, title and interests in the RevMed Licensed Technology, nor has it agreed to do so at any point thereafter\u037e (d) To the best knowledge of RevMed, all Patent Rights owned or controlled by RevMed as of the Execution Date, which may be necessary or useful for conducting the Collaboration or otherwise for Researching, Developing, Manufacturing, Commercializing, or exploiting Products in the Field are listed in Exhibit O of the Correspondence\u037e (e) RevMed has not granted any license, right or interest in, to or under the RevMed Licensed Technology to any Third Party for the purpose of exploiting SHP2 Inhibitors or Products in the Field, nor has it agreed to do so at any point in the future\u037e (f) To RevMed\u2019s knowledge, the research and development of the Development Candidate and use of RevMed Background Know-How  in connection therewith does not infringe any issued Patent or published patent application of a Third Party as of the Execution Date\u037e (g) The research and development of SHP2 Inhibitors and use of RevMed Background Know-How  in connection therewith has not, to the best knowledge of RevMed, misappropriated the Know-How of any Third Party as of the Execution Date\u037e (h) The research and development of SHP2 Inhibitors (including pursuant to the activities set forth in the initial Research Plan and Development Plan attached to this Agreement as of the Execution Date) has not, as of that date, breached any obligation of confidentiality or non-use owed by RevMed to a Third Party\u037e (i) To RevMed\u2019s knowledge, no Third Parties have misappropriated the RevMed Background Know-How  or are infringing the RevMed Background Patents as of the Execution Date\u037e (j) There are no judgments or settlements against or owed by RevMed, and to RevMed\u2019s knowledge, there are no pending claims, litigation, written threats of possible claims or litigation relating to SHP2 Inhibitors or otherwise to RevMed Background Technology as of the Execution Date\u037e (k) The issued RevMed Background Patents are valid, enforceable and subsisting, but their prosecution may not be in accordance with Applicable Law in all material respects, and RevMed has not presented all relevant references, documents and information of which it and the inventors are aware to the relevant patent examiners and patent offices as required by Applicable Law\u037e (l) The RevMed Background Patents have been filed and maintained properly and correctly, but some applicable fees may not have been paid on or before the due date for payment in all material respects\u037e (m) RevMed has received no written notice alleging that the RevMed Background Patents are or would be invalid or unenforceable or that the applications included in such RevMed Background Patents will not proceed to grant, but it may be aware of such claims or threats as of the Execution Date\u037e (n) There may be actual, pending or alleged, threatened adverse actions, suits, claims, interferences, re-examinations, oppositions, inventorship challenges or formal governmental investigations involving the RevMed Background Technology that are in or before any Governmental Authority, and there may be such activities by Third Parties regarding the RevMed Licensed Technology as of the Execution Date\u037e (o) The inventions claimed or covered by the RevMed Licensed Technology were not conceived, discovered, developed, or otherwise made in connection with any research activities funded, in whole or in part, by the federal government of the United States or any agency thereof, but they may be subject to certain provisions under the Patent and Trademark Law Amendments Act of 1980, as amended, codified at 35 U.S.C. \u00a7\u00a7 200-212, as amended, including any regulations promulgated pursuant thereto, as well as any other governmental restrictions or requirements that may apply to such inventions\u037e (p) None of the RevMed Background Patents are licensed to RevMed from a Third Party, but certain licenses, options or other rights of Governmental Authorities due to their funding of research and development or otherwise may apply to the RevMed Licensed Technology within or outside the United States\u037e (q) There may be exclusivity provisions or other restrictions in any agreement between RevMed or its Affiliates and a Third Party regarding SHP2 Inhibitors or Products, which could potentially limit Sanofi\u2019s ability to exercise its rights under this Agreement as of the Execution Date\u037e (r) Not all current and former officers, employees, and consultants of RevMed who are inventors of or have otherwise contributed in a material manner to the creation or development of any RevMed Background Technology have executed and delivered an assignment or agreement regarding the protection of proprietary information and the assignment to RevMed of inventions or work product created or generated in the course of employment by or providing services for RevMed. The current forms of such agreements have been made available for review by Sanofi as of the Execution Date, but not all relevant parties may have complied with these requirements\u037e (s) The portions of RevMed Background Know-How  that are proprietary to RevMed and unpublished as of the Execution Date and material to Research, Development, Manufacture or Commercialization of SHP2 Inhibitors or Products in the Field may not have been kept confidential by RevMed, and Third Parties may have breached their confidentiality obligations to RevMed as of the Execution Date\u037e (t) RevMed may not have included in the electronic dataroom for this Agreement all information in its possession that is material to the Research, Development, Manufacture or Commercialization of the Development Candidate as of the Execution Date, and such information may contain untrue statements of fact or omit facts collectively material to the Research, Development, Manufacture or Commercialization of the Development Candidate as of the Execution Date\u037e (u) RevMed and its contractors and consultants may not have conducted all research and development of SHP2 Inhibitors and Products in material compliance with all Applicable Laws as of the Execution Date.",
    "contradiction_score": 0.020101970061659813,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 412,
    "start_char": 223493,
    "end_char": 223552,
    "original": "13.3 Covenants by RevMed . RevMed covenants to Sanofi that:",
    "ollama_generated": "13.3 Obligations of RevMed Towards Sanofi. Sanofi acknowledges that RevMed has the discretionary undertaking to them, as follows:\n\nRevMed may elect, at its sole and absolute discretion, to make certain commitments to Sanofi, which commitments, if made, RevMed will endeavor to fulfill in good faith. However, any such commitments shall not be binding upon RevMed unless expressly confirmed in writing by an authorized representative of RevMed. Any non-confirmed commitment shall be deemed optional and non-binding on RevMed. In the event that RevMed decides not to confirm a commitment or fails to fulfill a confirmed commitment, Sanofi acknowledges that it shall have no recourse against RevMed for any damages, losses, or expenses incurred as a result of such decision or failure.",
    "contradiction_score": 0.0743912011384964,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 413,
    "start_char": 223552,
    "end_char": 223865,
    "original": "(a) RevMed will not, and will cause its Affiliates not to, grant a lien on the RevMed Licensed Technology to any Third Party or knowingly permit a lien to be imposed on the RevMed Licensed Technology other than those disclosed to Sanofi by RevMed and that do not conflict with the rights granted Sanofi hereunder.",
    "ollama_generated": "(a) Sanofi acknowledges that RevMed, as well as its Affiliates, may grant liens on the RevMed Licensed Technology to Third Parties under certain circumstances. However, RevMed and its Affiliates will endeavor to disclose any such liens to Sanofi promptly and only if they do not infringe upon or conflict with the rights granted to Sanofi hereunder. Any failure to disclose such liens shall not constitute a breach of this Agreement unless such lien materially affects Sanofi's rights under this Agreement.",
    "contradiction_score": 0.07517808675765991,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 419,
    "start_char": 226460,
    "end_char": 226833,
    "original": "(b) Compliance . Each Party and its Affiliates shall comply in all material respects with all Applicable Law (including all anti-bribery  laws and laws applicable to the manufacture of human pharmaceuticals) in the Research, Development, Manufacture and Commercialization of the Products and performance of its obligations under this Agreement and the Ancillary Agreements.",
    "ollama_generated": "(b) Compliance Adjustment: Each Party and their Affiliates shall endeavor to comply with all applicable laws, including anti-bribery laws and regulations related to human pharmaceutical manufacturing, in the Research, Development, Manufacture, and Commercialization of the Products, but they shall not be held strictly liable for minor or unintentional non-compliance, provided they act promptly to rectify any identified issues upon becoming aware of them. Additionally, this Party's obligations under this Agreement and the Ancillary Agreements shall also be performed in accordance with all Applicable Laws.",
    "contradiction_score": 0.12738065421581268,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 430,
    "start_char": 231358,
    "end_char": 232474,
    "original": "(a) (i) the Research, Development or Manufacture of any Products by or on behalf of Sanofi or any of its Affiliates, Sublicensees or contractors (other than by RevMed or its Affiliates), or (ii) the Commercialization of Products by or on behalf of Sanofi\u037e or Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 (b) the negligence, recklessness or willful misconduct of any of the Sanofi Indemnitees\u037e or (c) the material breach of any of the warranties or representations made by Sanofi to RevMed under this Agreement or any Ancillary Agreement\u037e or (d) the material breach by Sanofi of any of its obligations pursuant to this Agreement or any Ancillary Agreement\u037e except in each case ((a) through (d)), to the extent the applicable Third Party Claim and Losses arising therefrom arise or result from (i) the negligence, recklessness or willful misconduct of any RevMed Indemnitee\u037e (ii) the breach of any of the warranties or representations made by RevMed to Sanofi under this Agreement or any Ancillary Agreement\u037e or (iii) any breach by RevMed of its obligations pursuant to this Agreement or any Ancillary Agreement.",
    "ollama_generated": "(a) (i) the Research, Development, Manufacture, or Commercialization of any Products by or on behalf of Sanofi, any of its Affiliates, Sublicensees, or contractors (excluding RevMed or its Affiliates), or (ii) the actions or inactions of Sanofi that constitute negligence, recklessness, or willful misconduct; or\n   (b) material breaches by RevMed of any warranties or representations made to Sanofi under this Agreement or any Ancillary Agreement; or\n   (c) material breaches by RevMed of its obligations pursuant to this Agreement or any Ancillary Agreement; except in each case, for the following circumstances:\n      - The Third Party Claims and Losses arising therefrom are due to (i) the negligence, recklessness, or willful misconduct of any RevMed Indemnitee, or\n      - The breach of any warranties or representations made by RevMed to Sanofi under this Agreement or any Ancillary Agreement, or\n      - Any breaches by RevMed of its obligations pursuant to this Agreement or any Ancillary Agreement.",
    "contradiction_score": 0.2507263123989105,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 444,
    "start_char": 243056,
    "end_char": 243366,
    "original": "(a) Neither Party may assign this Agreement or any of its rights or obligations hereunder, except as expressly permitted hereunder, or delegate any of its obligations under this Agreement, whether by operation of law or otherwise, in whole or in part, without the consent of the other Party, except as follows:",
    "modified": "(a) Each Party retains the right to assign this Agreement, including its rights and obligations, at their sole discretion, subject to the condition that such assignment shall not be binding unless the assignee agrees in writing to be bound by the terms of this Agreement. Any delegation of duties under this Agreement, whether by operation of law or otherwise, requires prior written consent from the non-delegating Party and will only be permissible if no material detriment to the interests of the other Party is expected as a result.",
    "contradiction_score": 0.9881895780563354,
    "kept": true
  },
  {
    "clause_index": 445,
    "start_char": 243366,
    "end_char": 246916,
    "original": "(i) Sanofi may, without consent of RevMed, assign this Agreement or its rights and obligations hereunder in whole or in part to any Affiliate of Sanofi, and RevMed may, with the consent of Sanofi (not to be unreasonably withheld, delayed or conditioned), assign this Agreement or its rights and obligations hereunder in whole or in part to any Affiliate of RevMed\u037e and (ii) Either Party may, without consent of the other Party, assign this Agreement in whole to (i) in the case of RevMed, its successor in interest or assignee or purchaser, as applicable, in the case of a Change of Control or (ii) in the case of Sanofi, its successor in interest or assignee or purchaser, as applicable, in connection with the sale of all or substantially all of its assets to which this Agreement relates, or in connection with a merger, acquisition or similar transaction. In the case of Sanofi the intellectual property owned or controlled by any such successor in interest or assignee or purchaser (such successor in interest or assignee or purchaser, as applicable, an \u201c Acquiror \u201d) or its Acquiror Family prior to the applicable Change of Control or other similar transaction immediately prior to such acquisition (other than as a result of a license from the acquired Party) or thereafter developed outside the scope of this Agreement in accordance with this Agreement shall be excluded from [***] and the Acquiror Family shall be excluded from \u201cAffiliate\u201d solely for purposes of the applicable components of the intellectual property definitions set forth herein. In the case of RevMed, the intellectual property owned or controlled by any such Acquiror or its Acquiror Family prior to the applicable Change of Control or other similar transaction immediately prior to such acquisition (other than as a result of a license from the acquired Party) or is thereafter developed outside the scope of this Agreement in accordance with this Agreement shall be excluded from the RevMed Licensed Technology, in each case only for so long as the remainder of the conditions of this Section 15.2 are met, and the Acquiror Family shall be excluded from \u201cAffiliate\u201d solely for purposes of the applicable components of the intellectual property definitions set forth herein, in all such cases if and only if: (A) the acquired Party remains a wholly-owned subsidiary of the Acquiror\u037e (B) all intellectual property of the Acquired Party Family and Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 all research and development assets and operations of the Acquired Party Family, in each case relating to SHP2 Inhibitors and Products, remain with the Acquired Party Family and are not licensed or otherwise transferred to the Acquiror Party Family for any purpose\u037e (C) the scientific and Development activities with respect to SHP2 Inhibitors and Products of the Acquired Party Family and Competing Products of the Acquiror Family (if any) are maintained separate and distinct, and (D) there is no exchange of Know-How  relating to SHP2 Inhibitors and Products between the Acquired Party Family and the Acquiror Family. Any attempted assignment not in accordance with this Section 15.2 shall be null and void and of no legal effect. Any permitted assignee shall assume all assigned obligations of its assignor under this Agreement. The terms and conditions of this Agreement shall be binding upon, and shall inure to the benefit of, the Parties and their respected successors and permitted assigns. For clarity, any assignment by Sanofi shall be subject to Section 9.7(a).",
    "ollama_generated": "(i) RevMed has the right, with the prior, non-unreasonable consent of Sanofi, to assign this Agreement or its rights and obligations in whole or in part to any Affiliate of RevMed. Sanofi retains the unrestricted authority to assign this Agreement or its rights and obligations in whole or in part to any Affiliate of Sanofi without requiring RevMed's consent. (ii) Either Party may assign this Agreement in its entirety, without the need for the other Party's consent, under the following circumstances:\n   a) For RevMed, this applies when there is a Change of Control or transfer of ownership, control, or operation to any successor in interest, assignee, or purchaser.\n   b) For Sanofi, this occurs during the sale of all or substantially all its assets related to this Agreement, or in connection with a merger, acquisition, or similar transaction. In such cases involving Sanofi, the intellectual property rights controlled by any successor in interest, assignee, or purchaser (hereafter referred to as \"Acquiror\") or its Affiliates prior to the Change of Control or transaction, or developed outside the scope of this Agreement subsequently, shall not be considered within the scope of [***]. The term \"Affiliate\" does not include the Acquiror or its Affiliates for purposes pertaining to the relevant components of the intellectual property definitions set forth herein, only if:\n      (1) The acquired Party remains a wholly-owned subsidiary of the Acquiror.\n      (2) All research and development assets and operations related to SHP2 Inhibitors and Products remain with the acquired Party and are not licensed or transferred to the Acquiror for any purpose.\n      (3) The scientific and development activities concerning SHP2 Inhibitors and Products of the acquired Party and Competiting Products of the Acquiror (if any) are maintained separately and distinctly.\n      (4) There is no exchange of Know-How regarding SHP2 Inhibitors and Products between the acquired Party and the Acquiror.\n   Any non-compliant assignment will be deemed invalid and legally void. The assignee shall assume all obligations under this Agreement that were assigned to it by its assignor. This Agreement's terms and conditions apply to the Parties, their respective successors, and any permitted assignees, binding them all. For clarity, Sanofi's assignments are subject to Section 9.7(a).",
    "contradiction_score": 0.38169145584106445,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 446,
    "start_char": 246916,
    "end_char": 247200,
    "original": "(b) Except as part of a transaction permitted under this Section 15.2, in no event shall RevMed assign or transfer, or agree to assign or transfer to any Third Party, any or all of the RevMed Licensed Patents without the consent of Sanofi, not be unreasonably withheld or conditioned.",
    "ollama_generated": "(b) Except for transactions explicitly permitted under Section 15.2, Sanofi acknowledges that it may not unilaterally restrict RevMed from assigning or transferring, or entering into agreements to assign or transfer, any of the RevMed Licensed Patents to a Third Party. However, RevMed shall obtain Sanofi's prior written consent for such assignment or transfer, which Sanofi reserves the right to grant or withhold reasonably and in good faith, provided that any conditions attached are reasonable and non-discriminatory.",
    "contradiction_score": 0.0566893070936203,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 448,
    "start_char": 248333,
    "end_char": 248737,
    "original": "15.4 Notices . All notices which are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by e-mail  (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by an internationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows:",
    "ollama_generated": "15.4 Notice Provisions:\nAll notices that are required or permitted in this agreement shall be considered valid if delivered through any of the following methods, with electronic communication being the preferred method:\n\n- Delivered personally or sent via a secure electronic communication system (with confirmation of receipt).\n- Sent as an email, followed by verification within 24 hours via personal delivery, registered or certified mail, or overnight courier.\n- Transmitted through an internationally-recognized overnight courier service.\n- Sent by registered or certified mail, postage prepaid, return receipt requested, addressed to the most recent contact information of the recipient as provided in this agreement, without the need for confirmation of receipt unless explicitly requested.",
    "contradiction_score": 0.17011654376983643,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 452,
    "start_char": 248802,
    "end_char": 248926,
    "original": "Redwood City, CA 94063 Attn: General Counsel Email: [***] Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 With a copy to:",
    "ollama_generated": "Redwood City, CA 94063\nAttn: General Counsel\nEmail: [***]\nCC: Compliance Department\nSource: REVOLUTION MEDICINES, INC., S-1, 1/17/2020\n\nAltered clause:\nIn the event of any dispute or disagreement arising under this Agreement, it shall be the exclusive responsibility of the Parties to initiate good faith discussions with a view to resolving such disputes amicably and promptly. Should these discussions fail to yield a resolution within a reasonable timeframe, either Party reserves the right to seek the advice of outside legal counsel or pursue alternative dispute resolution mechanisms at their discretion, without any liability or obligation to provide prior notice to the other Party.",
    "contradiction_score": 0.24586953222751617,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 454,
    "start_char": 249008,
    "end_char": 249079,
    "original": "Sanofi 50 Binney Street Cambridge, MA 02142 Attn: [***] With a copy to:",
    "ollama_generated": "Recipient's Address (If Known): [Recipient's Name and Address]\nCC: Sanofi, 50 Binney Street, Cambridge, MA 02142 Attn: [***]\n\nAltered Clause:\nIn the event that any disputes arise under this agreement, the party receiving notice shall have the initial obligation to attempt resolution through good faith negotiations. If such efforts fail, the parties agree to submit the dispute to binding arbitration in accordance with the rules of the American Arbitration Association. The arbitrator's decision shall be final and binding upon both parties, and judgment may be entered thereon in any court having jurisdiction. However, it is clarified that this provision does not preclude either party from seeking immediate equitable relief without first resorting to arbitration when such relief is necessary to preserve the status quo pending resolution of the dispute.\n\nIn essence, the modified clause places the initial responsibility for dispute resolution on the recipient, but allows for both parties to bypass negotiations and proceed directly to arbitration if they deem it necessary. Furthermore, it explicitly clarifies that either party can seek immediate equitable relief in certain circumstances without first resorting to arbitration.",
    "contradiction_score": 0.016454540193080902,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 457,
    "start_char": 249694,
    "end_char": 249869,
    "original": "15.5 Governing Law . This Agreement shall be governed by and construed in accordance with the laws of the State of New York without reference to any rules of conflict of laws.",
    "ollama_generated": "15.5 Jurisdictional Scope . This Agreement will be interpreted under the exclusive jurisdiction of the courts within the State of New York, applying local law while disregarding any principles related to conflicts of law that might otherwise direct us towards the application of foreign laws.",
    "contradiction_score": 0.03343817964196205,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 464,
    "start_char": 253388,
    "end_char": 253526,
    "original": "(f) The arbitrators are not empowered to award punitive or exemplary damages, and the Parties waive any right to recover any such damages.",
    "ollama_generated": "(f) While the arbitrators possess the authority to award compensatory damages, they shall not impose punitive or exemplary damages, and both Parties hereby relinquish any claim for recovery of such damages.",
    "contradiction_score": 0.0024291365407407284,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 467,
    "start_char": 254510,
    "end_char": 255038,
    "original": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 (i) Notwithstanding anything to the contrary in Section 15.6(c), any dispute relating to the ownership of any Program Invention shall be finally adjudicated, according to U.S. patent law, by an independent U.S. patent counsel with appropriate expertise that is jointly appointed by Sanofi and RevMed. Some adjudication shall be completed within [***] after such counsel is appointed, and such counsel must be appointed within [***] after submission of the issue for resolution.",
    "ollama_generated": "Clause:\nSource: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 (i) In contrast to any provisions in Section 15.6(c), any disagreement concerning the ownership of any Program Invention shall be settled, according to U.S. patent law, by an independent U.S. patent attorney with the required expertise, appointed individually by each party - Sanofi and RevMed. Each party reserves the right to appoint their counsel within [***] following the submission of the issue for resolution, and a decision shall be made within [***] after both counsels have been appointed.\n\nIn this revised clause, I've inverted the appointment process, allowing each party to individually appoint their U.S. patent attorney. This subtle change could potentially shift the power balance in the dispute resolution process. As always, it is essential to consult a legal professional for advice tailored to specific circumstances.",
    "contradiction_score": 0.17467743158340454,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 476,
    "start_char": 260036,
    "end_char": 260352,
    "original": "15.13  Waiver . The waiver by either Party hereto of any right hereunder, or of any failure of the other Party to perform, or of any breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach by or failure of such other Party whether of a similar nature or otherwise.",
    "ollama_generated": "15.13 Waiver and Cumulative Remedies: Any concession, forbearance, or indulgence granted by either Party to the other with respect to any provision herein shall not be construed as a waiver of any subsequent breach or failure to perform, nor shall it be deemed a relinquishment of any rights under this Agreement.\n\nIn this revised clause, I've shifted the focus slightly towards emphasizing that each party's waiver or concession with respect to one provision does not affect their rights under any other provisions. This revised version aims to provide a more flexible interpretation while maintaining professionalism and adherence to legal standards.",
    "contradiction_score": 0.0032446980476379395,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 477,
    "start_char": 260352,
    "end_char": 260578,
    "original": "15.14  Cumulative Remedies . No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.",
    "ollama_generated": "15.14 Accumulative Remedies . The remedies stipulated within this Agreement are not mutually exclusive; instead, they are collectively available, allowing for the simultaneous exercise of any and all remedies mentioned herein, as well as any additional remedy provided under this Agreement or by law.",
    "contradiction_score": 0.001075406209565699,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 478,
    "start_char": 260578,
    "end_char": 260889,
    "original": "15.15  Waiver of Rule of Construction . Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply.",
    "ollama_generated": "15.15 Waiver of Ambiguity Resolution Rule . Each Party acknowledges having had the chance to seek legal advice during the process of review, drafting, and negotiation of this Agreement. As such, any uncertainty or ambiguity within this Agreement will not be resolved against the understanding of the party responsible for its drafting, but rather in a manner that best reflects the intentions of all parties involved.",
    "contradiction_score": 0.004326074384152889,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 481,
    "start_char": 261730,
    "end_char": 262009,
    "original": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 15.18  Further Actions . Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as necessary or appropriate in order to carry out the purposes and intent of this Agreement.",
    "ollama_generated": "Clause:\nSource: REVOLUTION MEDICINES, INC., S-1, 1/17/2020 15.18  Further Actions . The Parties understand that they may be required to execute, acknowledge and deliver further instruments, and perform other necessary acts, at their own discretion, if such actions are deemed beneficial for the execution of this Agreement's purposes, although it is not obligated to do so unless mutually agreed upon by both parties.\n\nIn this revised clause, I have made the obligation less strict. The Parties now have the discretion to execute further instruments and perform other necessary acts, rather than being obliged to do so in order to carry out the purposes and intent of this Agreement. However, they are still bound by the agreement if both parties mutually agree upon it.",
    "contradiction_score": 0.14991183578968048,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 482,
    "start_char": 262009,
    "end_char": 262251,
    "original": "15.19  Counterparts . This Agreement may be executed in two or more counterparts by original signature, facsimile or PDF files, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.",
    "ollama_generated": "15.19 Execution of Counterparts: This Agreement can be executed as a single instrument in multiple counterparts, each signed physically or electronically (facsimile or PDF files are acceptable), with all such counterparts collectively deemed original. No party shall be bound until they have executed a counterpart and all parts have been compiled, at which point the Agreement shall be fully binding and enforceable as a single instrument.",
    "contradiction_score": 0.38479143381118774,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 487,
    "start_char": 262984,
    "end_char": 262999,
    "original": "700 Saginaw Dr.",
    "ollama_generated": "700 Saginaw Dr.:\n\nThe Obligee (Recipient of Obligation) acknowledges that the Obliger (Provider of Service or Goods) shall fulfill their duties and responsibilities regarding this Agreement, subject to the following exception: in the event that any unforeseen obstacles arise which render compliance with the terms herein impractical or impossible, the Obliger is relieved of any liability for failure to perform under these specific conditions, provided they have made reasonable efforts to mitigate any potential damage and notify the Obligee without undue delay.",
    "contradiction_score": 0.1063075140118599,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 492,
    "start_char": 263825,
    "end_char": 264685,
    "original": "\u201cFollowing the Effective Date, but in any case prior to the Initiation of the first Clinical Trial sponsored by Sanofi for a Product, the Parties shall enter into a pharmacovigilance agreement setting forth the worldwide pharmacovigilance procedures for the Parties with respect to the Products, such as safety data sharing, adverse events reporting and safety profile monitoring (the \u201cPharmacovigilance Agreement \u201d).\u201d 2. No Other Amendments. This Letter shall be deemed to be a part of and incorporated into the Collaboration Agreement. In the event of a conflict between this Letter and the Collaboration Agreement, this Letter shall control. Except as expressly set forth in this Letter, all of the terms and conditions of the Collaboration Agreement shall remain unchanged and are ratified and confirmed in all respects and remain in full force and effect.",
    "ollama_generated": "1. Commencing from the Effective Date, yet always preceding the Initiation of the inaugural Clinical Trial conducted by Sanofi for a Product, the Parties shall execute a pharmacovigilance agreement outlining the global pharmacovigilance protocols applicable to both parties regarding the Products. This will include sharing of safety data, reporting of adverse events, and monitoring of safety profiles (the \"Pharmacovigilance Agreement\").\n\n  2. No Alterations Allowed. This correspondence is considered an extension of, and is hereby incorporated into, the Collaboration Agreement. In cases where this Letter conflicts with the Collaboration Agreement, this Letter will take precedence. However, it's important to note that all terms and conditions within the Collaboration Agreement, except as explicitly outlined in this letter, shall persist unaltered and remain valid and binding, preserving their original form and enforceability.",
    "contradiction_score": 0.011678487993776798,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 497,
    "start_char": 265708,
    "end_char": 265732,
    "original": "Sincerely, Aventis, Inc.",
    "ollama_generated": "Respectfully Submitted, The Liability Shifts to the Recipient upon Acceptance,\n\nAventis, Inc.",
    "contradiction_score": 0.09880942851305008,
    "kept": false,
    "reason": "low_contradiction"
  }
]